Search by Journal
- HOME
- > Search by Journal
- > Journal of Japanese Society of Pharmaceutical Oncology
Journal of Japanese Society of Pharmaceutical Oncology
Volume 15, Issue / 2020
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
Meet a changing thing, the academic meeting of thing - JASPO ninth which does not change; and ... 山本弘史 Journal of Japanese Society of Pharmaceutical Oncology 15: 1-1, 2020. |
|---|
|
|
From mitochondrial - parasite as the drug target to a cancer cell - 北潔 Journal of Japanese Society of Pharmaceutical Oncology 15: 2-2, 2020. |
|---|
|
|
Progress and lung cancer of the genomic medicine 中西洋一 Journal of Japanese Society of Pharmaceutical Oncology 15: 3-3, 2020. |
|---|
|
|
Pharmacist (the coming cancer medical figure which revised pharmaceutical products medical equipment law aims at) who snuggles up to the patients living with a cancer 森和彦 Journal of Japanese Society of Pharmaceutical Oncology 15: 4-4, 2020. |
|---|
|
|
BS1. Point of basic knowledge and the medication counseling of the blood cancer 櫻井洋臣 Journal of Japanese Society of Pharmaceutical Oncology 15: 5-5, 2020. |
|---|
|
|
BS2. The knowledge that we want to know of the stomach cancer medical therapy 岩井美奈 Journal of Japanese Society of Pharmaceutical Oncology 15: 6-6, 2020. |
|---|
|
|
BS3. Urologic cancer 小暮友毅 Journal of Japanese Society of Pharmaceutical Oncology 15: 7-7, 2020. |
|---|
|
|
BS4. The management of the febrile neutropenia 高田慎也 Journal of Japanese Society of Pharmaceutical Oncology 15: 8-8, 2020. |
|---|
|
|
BS5. Immune-mediated adverse event (irAE) and the measures 池末裕明 Journal of Japanese Society of Pharmaceutical Oncology 15: 9-9, 2020. |
|---|
|
|
BS6. Dermatopathy with the treatment with anticancer medicine 松井礼子 Journal of Japanese Society of Pharmaceutical Oncology 15: 10-10, 2020. |
|---|
|
|
BS7. The basics of lung cancer medical therapy 中田英夫 Journal of Japanese Society of Pharmaceutical Oncology 15: 11-11, 2020. |
|---|
|
|
BS8. Basic knowledge of the antiemetic which is useful for prescription suggestion 鈴木賢一 Journal of Japanese Society of Pharmaceutical Oncology 15: 12-12, 2020. |
|---|
|
|
BS9. Standard therapy of colon cancer treatment 青山剛 Journal of Japanese Society of Pharmaceutical Oncology 15: 13-13, 2020. |
|---|
|
|
BS10. Breast cancer 宮本康敬 Journal of Japanese Society of Pharmaceutical Oncology 15: 14-14, 2020. |
|---|
|
|
Nippon BS Broadcasting. The management of the diarrhea with cancer treatment 大橋養賢 Journal of Japanese Society of Pharmaceutical Oncology 15: 15-15, 2020. |
|---|
|
|
BS12. Of the basic knowledge and medical therapy of the malignant lymphoma, actually 小笠原信敬 Journal of Japanese Society of Pharmaceutical Oncology 15: 16-16, 2020. |
|---|
|
|
The world breast cancer medical care is ... breast cancer and pink ribbon activity ... now 大野真司 Journal of Japanese Society of Pharmaceutical Oncology 15: 17-17, 2020. |
|---|
|
|
Social pain and support - supportive care - that illness causes it 坂本はと恵 Journal of Japanese Society of Pharmaceutical Oncology 15: 18-18, 2020. |
|---|
|
|
S1-1. Basic knowledge of the cancer immunity that we want to suppress 玉田耕治 Journal of Japanese Society of Pharmaceutical Oncology 15: 20-20, 2020. |
|---|
|
|
S1-2. Where did the "cancer immune therapy guidelines second edition" latest guidelines change? 馬場英司 Journal of Japanese Society of Pharmaceutical Oncology 15: 21-21, 2020. |
|---|
|
|
S1-3. "Rules" that you should know as irAE - clinical pharmacist ... 吉野真樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 22-22, 2020. |
|---|
|
|
S1-4. Cancer immune therapy, problem in the future, How does CQ raise it? 鈴木賢一 Journal of Japanese Society of Pharmaceutical Oncology 15: 23-23, 2020. |
|---|
|
|
Symposium 2. Than efforts - organizer of the pharmacist to antiemesis therapy improvement ... 飯原大稔 Journal of Japanese Society of Pharmaceutical Oncology 15: 24-24, 2020. |
|---|
|
|
S2-1. Phase III study (J-FORCE) which tests the addition of 5 mg of olanzapine to standard antiemesis therapy 橋本浩伸 Journal of Japanese Society of Pharmaceutical Oncology 15: 25-25, 2020. |
|---|
|
|
S2-2. Efforts to individualization of the antiemesis therapy for the cancer chemotherapy based on the patients risk factor 益子寛之 Journal of Japanese Society of Pharmaceutical Oncology 15: 26-26, 2020. |
|---|
|
|
S2-3. It is ... from the viewpoint of efforts - PGx to individualization of the antiemesis therapy for the cancer chemotherapy 辻大樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 27-27, 2020. |
|---|
|
|
S2-4. How make up for lack of the evidence; is ... through a national survey of ... olanzapine 林稔展 Journal of Japanese Society of Pharmaceutical Oncology 15: 28-28, 2020. |
|---|
|
|
Symposium 3. Than mouth care and supportive care - organizer in patients with cancer ... 林稔展, 合澤啓二 Journal of Japanese Society of Pharmaceutical Oncology 15: 29-29, 2020. |
|---|
|
|
S3-1. It is ... from the situation of importance - dentist of the mouth care 山添淳一 Journal of Japanese Society of Pharmaceutical Oncology 15: 30-30, 2020. |
|---|
|
|
S3-2. Activity of the mouth care support team in conjunction with NST 石川寛 Journal of Japanese Society of Pharmaceutical Oncology 15: 31-31, 2020. |
|---|
|
|
S3-3. Battle front of the oral supportive care 渡邉真一 Journal of Japanese Society of Pharmaceutical Oncology 15: 32-32, 2020. |
|---|
|
|
Symposium 4. Share the trouble of each institution, and think together, and let's connect it with duties from tomorrow; than on-site trouble of the pharmacist outpatient department and future way - organizer ...! 藤堂真紀, 郷真貴子 Journal of Japanese Society of Pharmaceutical Oncology 15: 33-33, 2020. |
|---|
|
|
S4-1. It has just begun until now of the ambulatory service (pharmacist outpatient department) of the pharmacist in the cancer medical therapy 藤堂真紀 Journal of Japanese Society of Pharmaceutical Oncology 15: 34-34, 2020. |
|---|
|
|
S4-2. Having learned from experience in the pharmacist outpatient department, the thing that we want to convey 郷真貴子 Journal of Japanese Society of Pharmaceutical Oncology 15: 35-35, 2020. |
|---|
|
|
S4-3. We think about the future until duties system construction of the pharmacist outpatient department 平畠正樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 36-36, 2020. |
|---|
|
|
S4-4. How does side effect management - pharmacist estimate the patients as adherence improvement? - to think about this 阪田安彦 Journal of Japanese Society of Pharmaceutical Oncology 15: 37-37, 2020. |
|---|
|
|
S4-5. Medicine medicine cooperation and the next generation education in the pharmacist outpatient department 槇原洋子, 秦晃二郎, 渡邊裕之 Journal of Japanese Society of Pharmaceutical Oncology 15: 38-38, 2020. |
|---|
|
|
Symposium 5. Than current situation of the anticancer medicine exposure study and future ... organizer ... 野村久祥 Journal of Japanese Society of Pharmaceutical Oncology 15: 39-39, 2020. |
|---|
|
|
S5-1. The current situation of the anticancer medicine exposure study 石丸博雅 Journal of Japanese Society of Pharmaceutical Oncology 15: 40-40, 2020. |
|---|
|
|
S5-2. Gap of the anticancer medicine exposure measures study 佐藤淳也 Journal of Japanese Society of Pharmaceutical Oncology 15: 41-41, 2020. |
|---|
|
|
S5-3. The dispatch from the healthcare setting of anticancer medicine exposure measures and future directionality 濱宏仁 Journal of Japanese Society of Pharmaceutical Oncology 15: 42-42, 2020. |
|---|
|
|
S5-4. Efforts to the study that intended standardization of the exposure monitoring 佐野慶行 Journal of Japanese Society of Pharmaceutical Oncology 15: 43-43, 2020. |
|---|
|
|
Symposium 6. Than yew women health - organizer supporting the total health care of patients with female cancer ... 日置三紀, 牧野あずみ Journal of Japanese Society of Pharmaceutical Oncology 15: 44-44, 2020. |
|---|
|
|
S6-1. It is ... with the yew women health becoming the move named "cancer, watershed - next of reproductive medicine" which a physician thinks about 太田邦明, 高橋俊文 Journal of Japanese Society of Pharmaceutical Oncology 15: 45-45, 2020. |
|---|
|
|
S6-2. There is it as ... hospital pharmacist with the support which women can draw wonderful life plan after cancer treatment 赤阪未来 Journal of Japanese Society of Pharmaceutical Oncology 15: 46-46, 2020. |
|---|
|
|
S6-3. The support that "the family pharmacist" to area women living with a cancer is available for 宮原富士子1,2,3) Journal of Japanese Society of Pharmaceutical Oncology 15: 47-47, 2020. |
|---|
|
|
Symposium 7. How do elderly people cancer treatment, the pharmacist support it? Than ... organizer ... 魚井みゆき Journal of Japanese Society of Pharmaceutical Oncology 15: 48-48, 2020. |
|---|
|
|
S7-1. Usefulness of the elderly people usability test in the cancer medical care of elderly people 西嶋智洋 Journal of Japanese Society of Pharmaceutical Oncology 15: 49-49, 2020. |
|---|
|
|
S7-2. About a point to be careful about as a pharmacist contacting patients with old cancer 宮澤憲治 Journal of Japanese Society of Pharmaceutical Oncology 15: 50-50, 2020. |
|---|
|
|
S7-3. Team approach in elderly people cancer treatment 那須いずみ Journal of Japanese Society of Pharmaceutical Oncology 15: 51-51, 2020. |
|---|
|
|
S7-4. Efforts ... in medical therapy support - Kanazawa of patients with at-home cancer by the drugstore pharmacist 小林星太 Journal of Japanese Society of Pharmaceutical Oncology 15: 52-52, 2020. |
|---|
|
|
Symposium 8. Than practice - organizer of the team approach in medical care in the cancer genomic medicine ... 米村雅人, 池見泰明 Journal of Japanese Society of Pharmaceutical Oncology 15: 53-53, 2020. |
|---|
|
|
S8-1. Practice of the cancer genomic medicine 西原広史 Journal of Japanese Society of Pharmaceutical Oncology 15: 54-54, 2020. |
|---|
|
|
S8-2. Collecting how to handle role - cancer genome information as the pharmacist, how to convey - 櫻井洋臣 Journal of Japanese Society of Pharmaceutical Oncology 15: 55-55, 2020. |
|---|
|
|
Symposium 9. Than thing - organizer who want to know in conducting the rearward observational study that intended for an abecedarian ... 橋本浩伸, 河添仁 Journal of Japanese Society of Pharmaceutical Oncology 15: 57-57, 2020. |
|---|
|
|
S9-1. ... that the purpose of the study turns ... PDCA cycle for the patients 河添仁 Journal of Japanese Society of Pharmaceutical Oncology 15: 58-58, 2020. |
|---|
|
|
S9-2. ... to learn from real - failure of the rearward observational study 高橋克之 Journal of Japanese Society of Pharmaceutical Oncology 15: 59-59, 2020. |
|---|
|
|
S9-3. We can learn from meaning and practice - past example of the quality control of data of the management 種村菜奈枝 Journal of Japanese Society of Pharmaceutical Oncology 15: 60-60, 2020. |
|---|
|
|
S9-4. ... to look back toward rationale from important ... resident education in studying it 橋本浩伸 Journal of Japanese Society of Pharmaceutical Oncology 15: 61-61, 2020. |
|---|
|
|
Symposium 10. Than skill - organizer demanded from cancer medical therapy and the pharmacist in the super aging society ... 内山将伸 Journal of Japanese Society of Pharmaceutical Oncology 15: 62-62, 2020. |
|---|
|
|
S10-1. We regard cancer medical therapy as the characteristic of patients with old cancer from an usability test 田村和夫 Journal of Japanese Society of Pharmaceutical Oncology 15: 63-63, 2020. |
|---|
|
|
S10-2. Clinical reactions of drugs of the elderly people who should be careful in the cancer medical therapy 藤田行代志 Journal of Japanese Society of Pharmaceutical Oncology 15: 64-64, 2020. |
|---|
|
|
S10-3. Way of thinking by the handling of patients with old cancer in the clinical study and the practical practice 丹田雅明 Journal of Japanese Society of Pharmaceutical Oncology 15: 65-65, 2020. |
|---|
|
|
S10-4. Observational, prospective study ... using elderly people usability test - chemotherapy toxic predictive tool (CARG-score) that a pharmacist practices 内山将伸 Journal of Japanese Society of Pharmaceutical Oncology 15: 66-66, 2020. |
|---|
|
|
Symposium 11. Than ... organizer regarding the future as the current situation of the Biosimilar ... 渡邊裕之 Journal of Japanese Society of Pharmaceutical Oncology 15: 67-67, 2020. |
|---|
|
|
S11-1. Development - production, quality, equivalence trial ... of the Biosimilar 山田正敏 Journal of Japanese Society of Pharmaceutical Oncology 15: 68-68, 2020. |
|---|
|
|
S11-2. Problem to basic knowledge and the spread of Biosimilar 鈴木貴明 Journal of Japanese Society of Pharmaceutical Oncology 15: 69-69, 2020. |
|---|
|
|
S11-3. Effect (about safety, usefulness, economy) of the Biosimilar 池田龍二 Journal of Japanese Society of Pharmaceutical Oncology 15: 70-70, 2020. |
|---|
|
|
Symposium 12. To understand the study using the pit fall spontaneous report database of the signal detection, and to inflect; than ... organizer ... 漆原尚巳 Journal of Japanese Society of Pharmaceutical Oncology 15: 71-71, 2020. |
|---|
|
|
S12-1. Spontaneous report (side effect report) in the pharmaceutical company and database - scenery and utilization - 宮崎真 Journal of Japanese Society of Pharmaceutical Oncology 15: 72-72, 2020. |
|---|
|
|
S12-2. A theory and pit fall of the signal detection 漆原尚巳 Journal of Japanese Society of Pharmaceutical Oncology 15: 73-73, 2020. |
|---|
|
|
S12-3. The matter which should note it in a data mining study using JADER 酒井隆全 Journal of Japanese Society of Pharmaceutical Oncology 15: 74-74, 2020. |
|---|
|
|
S13-1. For clinical business training to apply it on the site, and to practice 猪田宏美 Journal of Japanese Society of Pharmaceutical Oncology 15: 76-76, 2020. |
|---|
|
|
S13-2. See it for "acquirement"; became it; accumulate; the clinic curriculum of the type 北原加奈之 Journal of Japanese Society of Pharmaceutical Oncology 15: 77-77, 2020. |
|---|
|
|
S13-3. It is ... for the development of pharmacist duties of upbringing - future of the prospective pharmacist 木村緑 Journal of Japanese Society of Pharmaceutical Oncology 15: 78-78, 2020. |
|---|
|
|
S13-4. Upbringing and expanse of the pharmacist supporting the cancer medical therapy that met the new development 池末裕明 Journal of Japanese Society of Pharmaceutical Oncology 15: 79-79, 2020. |
|---|
|
|
Symposium 14. Than Current and next in clinical oncology pharmacists in Asia - organizer ... 鈴木真也 Journal of Japanese Society of Pharmaceutical Oncology 15: 80-80, 2020. |
|---|
|
|
S14-1. Aim with the current situation of Oncology Pharmacy in Japan from now on 鈴木真也 Journal of Japanese Society of Pharmaceutical Oncology 15: 81-81, 2020. |
|---|
|
S14-2. Current status of Oncology Pharmacy in China and future goals[Machine Translation] (中国におけるOncology Pharmacyの現状とこれから目指すこと) Yu Bo Journal of Japanese Society of Pharmaceutical Oncology 15: 82-82, 2020. |
|---|
|
|
S14-3. Current status of Oncology Pharmacy in Singapore and future goals[Machine Translation] (シンガポールにおけるOncology Pharmacyの現状とこれから目指すこと) Peter Yap Journal of Japanese Society of Pharmaceutical Oncology 15: 83-83, 2020. |
|---|
|
|
S14-4. Current status of Oncology Pharmacy in Thailand and future goals[Machine Translation] (タイにおけるOncology Pharmacyの現状とこれから目指すこと) Suphat Subongkot Journal of Japanese Society of Pharmaceutical Oncology 15: 84-84, 2020. |
|---|
|
|
Symposium 15. It is not easy? Than "way of thinking" that is indispensable to approach - hospital, drugstore pharmacist to an adverse event of the new age in being common - - organizer ... 川口崇, 松尾宏一 Journal of Japanese Society of Pharmaceutical Oncology 15: 85-85, 2020. |
|---|
|
|
S15-1. Basics of the adverse event evaluation in cancer treatment 川口崇1,2) Journal of Japanese Society of Pharmaceutical Oncology 15: 86-86, 2020. |
|---|
|
|
S15-2. It is ... through the example of patients with approach - kidney cancer to a cancer treatment adverse event to be associated with 東加奈子 Journal of Japanese Society of Pharmaceutical Oncology 15: 87-87, 2020. |
|---|
|
|
S15-3. Support example (drugstore pharmacist edition) for the side effect of anticancer medicine-treated patients and the adverse event 長久保久仁子 Journal of Japanese Society of Pharmaceutical Oncology 15: 88-88, 2020. |
|---|
|
|
S15-4. From the viewpoint of way of thinking - physician of the information sharing with the pharmacist - 岸田直樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 89-89, 2020. |
|---|
|
|
Symposium 16. Fix the eyes on enforcement of the pharmaceutical management that continued after formulations; and than ... organizer ... 高橋郷, 村田勇人 Journal of Japanese Society of Pharmaceutical Oncology 15: 90-90, 2020. |
|---|
|
|
S16-1. Pharmaceutical management ... for pharmaceutical management 1 - inpatient who continued after the formulations in the hospital 槇枝大貴 Journal of Japanese Society of Pharmaceutical Oncology 15: 91-91, 2020. |
|---|
|
|
S16-2. Pharmaceutical management ... for pharmaceutical management 2 - outpatient who continued after the formulations in the hospital 藤宮龍祥1,2) Journal of Japanese Society of Pharmaceutical Oncology 15: 92-92, 2020. |
|---|
|
|
S16-3. Pharmaceutical management ... using pharmaceutical management 1 - tracing report which continued after the formulations in the health insurance pharmacy 久田健登 Journal of Japanese Society of Pharmaceutical Oncology 15: 93-93, 2020. |
|---|
|
|
S16-4. Pharmaceutical management ... by pharmaceutical management 2 - telephone follow-up that continued after the formulations in the health insurance pharmacy 丹原由希 Journal of Japanese Society of Pharmaceutical Oncology 15: 94-94, 2020. |
|---|
|
|
Symposium 17. You write it, and how do you tell how? Than the Tips - organizer of an example report and the interview in the APACC authorized study ... 小井土啓一, 浅野智央 Journal of Japanese Society of Pharmaceutical Oncology 15: 95-95, 2020. |
|---|
|
|
S17-1. About importance, the need of the interview in the example report 村上明男 Journal of Japanese Society of Pharmaceutical Oncology 15: 96-96, 2020. |
|---|
|
|
S17-2. Measures of making and the interview examination of the submission example 小賀春菜 Journal of Japanese Society of Pharmaceutical Oncology 15: 97-97, 2020. |
|---|
|
|
S17-3. The review of the submission example and evaluation of the interview 橋口宏司 Journal of Japanese Society of Pharmaceutical Oncology 15: 98-98, 2020. |
|---|
|
|
S17-4. Measures of example examination in the foreign cancer treatment authorization pharmacist (APACC) authorized acquisition and the interview examination 本田容子 Journal of Japanese Society of Pharmaceutical Oncology 15: 99-99, 2020. |
|---|
|
|
S17-5. It is ... from the situation of the point - review person, interview official of example review and the interview evaluation for the APACC acquisition 小室雅人 Journal of Japanese Society of Pharmaceutical Oncology 15: 100-100, 2020. |
|---|
|
|
S17-6. You report an example, and you write it, and how do you want you to tell how? 小井土啓一1,2) Journal of Japanese Society of Pharmaceutical Oncology 15: 101-101, 2020. |
|---|
|
|
Symposium 18. Step on one step at the beginning to a pharmacist supporting ... cancer medical therapy, and seem to appear to the pharmacist feeling a wall to patients with cancer in front now; than ... organizer ... 下川友香理 Journal of Japanese Society of Pharmaceutical Oncology 15: 102-102, 2020. |
|---|
|
|
S18-1. To get over "an obstacle" when a health insurance pharmacy pharmacist is concerned with patients with cancer? 本田雅志 Journal of Japanese Society of Pharmaceutical Oncology 15: 103-103, 2020. |
|---|
|
|
S18-2. Efforts in the area aiming at qualitative improvement of the medication counseling to patients with cancer 衛藤智章 Journal of Japanese Society of Pharmaceutical Oncology 15: 104-104, 2020. |
|---|
|
|
S18-3. Know-how of the blocking cancellation of the pharmacist judging from Shizuoka classification 石川寛 Journal of Japanese Society of Pharmaceutical Oncology 15: 105-105, 2020. |
|---|
|
|
Symposium 19. Than ... organizer thinking in a situation of each relation ... physician, hospital pharmacist, health insurance pharmacy pharmacist of the pharmacist in the advance care planning ... 山本紗織 Journal of Japanese Society of Pharmaceutical Oncology 15: 106-106, 2020. |
|---|
|
|
S19-1. From the situation of knowledge and practice - treatment medicine of the advance care planning - 相良安昭 Journal of Japanese Society of Pharmaceutical Oncology 15: 107-107, 2020. |
|---|
|
|
S19-2. Hospital pharmacist can do it to support each person's hope 川尻尚子 Journal of Japanese Society of Pharmaceutical Oncology 15: 108-108, 2020. |
|---|
|
|
S19-3. Support from the situation of the health insurance pharmacy pharmacist thinking about the way of life like the person 谷本愛 Journal of Japanese Society of Pharmaceutical Oncology 15: 109-109, 2020. |
|---|
|
|
Symposium 20. Than ... organizer thinking about the relation role - pharmacist of the health insurance pharmacy pharmacist in the foreign cancer medical therapy ... 稲葉一郎 Journal of Japanese Society of Pharmaceutical Oncology 15: 110-110, 2020. |
|---|
|
|
S20-1. Upbringing training plan of the coping pharmacist to extensive pharmaceutical management needs 近藤元三 Journal of Japanese Society of Pharmaceutical Oncology 15: 111-111, 2020. |
|---|
|
|
S20-2. The thing which is bought in the current situation and the health insurance pharmacy of the cancer practice of Kumamoto 境健爾 Journal of Japanese Society of Pharmaceutical Oncology 15: 112-112, 2020. |
|---|
|
|
S20-3. As a family drugstore of ... area supporting patients with cancer with the whole drugstore ... 中島美紀 Journal of Japanese Society of Pharmaceutical Oncology 15: 113-113, 2020. |
|---|
|
|
S20-4. The cancer medical therapy management and pharmacist cooperation (from the situation of the hospital pharmacist) 山室蕗子 Journal of Japanese Society of Pharmaceutical Oncology 15: 114-114, 2020. |
|---|
|
|
Symposium 21. Than "regimen" and "regimen order" - organizer saving patients with cancer ... 山口健太郎 Journal of Japanese Society of Pharmaceutical Oncology 15: 115-115, 2020. |
|---|
|
|
S21-1. The current situation and problem of the regimen system 井上貴宏 Journal of Japanese Society of Pharmaceutical Oncology 15: 116-116, 2020. |
|---|
|
|
S21-2. The regimen order system which a medical information manager thinks about 小暮友毅 Journal of Japanese Society of Pharmaceutical Oncology 15: 117-117, 2020. |
|---|
|
|
S21-3. Regimen management in the university hospital 山口健太郎 Journal of Japanese Society of Pharmaceutical Oncology 15: 118-118, 2020. |
|---|
|
|
S21-4. Regimen management and invention of electronic chart introduction seven years 柿原圭佑 Journal of Japanese Society of Pharmaceutical Oncology 15: 119-119, 2020. |
|---|
|
|
Symposium 22. Than ... organizer thinking about the concentration method of the local pharmacist power to build the safe and effective cancer medical therapy offer system ... 岸本真, 川崎美紀 Journal of Japanese Society of Pharmaceutical Oncology 15: 120-120, 2020. |
|---|
|
|
S22-1. About efforts to medicine medicine cooperation of the cancer medical care in the Shimonoseki district 塚原邦浩 Journal of Japanese Society of Pharmaceutical Oncology 15: 121-121, 2020. |
|---|
|
|
S22-2. Efforts of the medicine medicine cooperation using the cancer side effect monitoring sheet in Kagoshima 御手洗洋一 Journal of Japanese Society of Pharmaceutical Oncology 15: 122-122, 2020. |
|---|
|
|
S22-3. Cancer practice cooperation base Hospital being done to examine illness, and to be able to connect to the medicine cooperation, the thing that you should do 上ノ段友里 Journal of Japanese Society of Pharmaceutical Oncology 15: 123-123, 2020. |
|---|
|
|
S22-4. For opening to a local pharmacist of Caner Board and collaboration in there 岸本真 Journal of Japanese Society of Pharmaceutical Oncology 15: 124-124, 2020. |
|---|
|
|
Symposium 23. Than specialized medical institution cooperation drugstore - organizer thinking from the APACC acquisition ... 中島寿久, 石森雅人 Journal of Japanese Society of Pharmaceutical Oncology 15: 125-125, 2020. |
|---|
|
|
S23-1. Medicine medicine cooperation for the purpose of the APACC acquisition 国吉央城 Journal of Japanese Society of Pharmaceutical Oncology 15: 126-126, 2020. |
|---|
|
|
S23-2. The thing which we obtained from medicine medicine cooperation 水井亮 Journal of Japanese Society of Pharmaceutical Oncology 15: 127-127, 2020. |
|---|
|
|
S23-3. What we failed in doing the authorized acquisition at a health insurance pharmacy and got over 村田勇人 Journal of Japanese Society of Pharmaceutical Oncology 15: 128-128, 2020. |
|---|
|
|
S23-4. Of the activity of APACC in the health insurance pharmacy, actually 下川友香理 Journal of Japanese Society of Pharmaceutical Oncology 15: 129-129, 2020. |
|---|
|
|
S23-5. For the specialty that is higher than APACC acquisition - by the health insurance pharmacy pharmacist - 葉山達也 Journal of Japanese Society of Pharmaceutical Oncology 15: 130-130, 2020. |
|---|
|
|
O-02. Investigation about the hiccups onset factor 吉田文, 須藤弥生, 品川理加, 増田智美, 小林敦 Journal of Japanese Society of Pharmaceutical Oncology 15: 132-132, 2020. |
|---|
|
|
O-03. Examination about the serum creatinine rise in the cyclin-dependent kinase (CDK) 4/6 inhibitor Abemaciclib 高木麻里, 足立茜子, 高橋幸三, 角川幸男, 藤田敬子 Journal of Japanese Society of Pharmaceutical Oncology 15: 133-133, 2020. |
|---|
|
|
O-04. Examination about the effectiveness of the second prophylaxis of the peg filgrastim in the chemotherapy for the non-Hodgkin's lymphoma 小中健1,2), 斉藤辰彦1,2), 宮森弘子1,2), 森剛志1), 森本美由樹2), 橋本年弘3), 伏谷秀治1) Journal of Japanese Society of Pharmaceutical Oncology 15: 134-134, 2020. |
|---|
|
|
O-05. Effect on blood vessel with Foss aprepitant 須藤弥生1), 今井洋子2), 吉田文1), 品川理加1), 増田智美1), 小林敦1) Journal of Japanese Society of Pharmaceutical Oncology 15: 135-135, 2020. |
|---|
|
|
O-06. Comparison ... of infution reaction for safe examination - aggressive non - Hodgkin lymphoma in biogeneric drug rituximab BS 天野詩織1), 井上裕貴1), 竹田あかね1), 中井正彦1), 飯田浩充2), 永井宏和2) Journal of Japanese Society of Pharmaceutical Oncology 15: 136-136, 2020. |
|---|
|
|
O-07. The effect that the BMI of patients with small cell lung cancer gives to expression of the thrombocytopenia by the Carboplatin: We look at the rear and study a mark 根來寛1), 重森美奈1), 小島すみれ1), 山下慎司1), 渡邉享平1,2), 矢野良一1), 塚本仁1), 後藤伸之1) Journal of Japanese Society of Pharmaceutical Oncology 15: 137-137, 2020. |
|---|
|
|
O-08. Making ... of the side effect evaluation tool common throughout efforts - drugstore and a hospital to oral anticancer agent medication counseling elimination 磯崎弘恵1), 計良貴之2), 塩川尚恵2), 長澤敬輔3), 竹川亮4), 機田千鶴子5), 渡邉典江1), 湊川紘子2) Journal of Japanese Society of Pharmaceutical Oncology 15: 138-138, 2020. |
|---|
|
|
O-09. Evaluation of the usefulness of the peg filgrastim for the pyrogenic neutropenic prevention in the amrubicin therapy as the second treatment for small-cell lung cancer 佐藤幸奈1), 飯原大稔1,2), 木野村元彦1), 廣瀬智恵美1), 遠渡純輝3), 柳瀬恒明3), 垣内大蔵3), 佐々木優佳3), 五明岳展3), 酒井千鶴3), 岩井正道3), 大野康3), 鈴木昭夫1,2) Journal of Japanese Society of Pharmaceutical Oncology 15: 139-139, 2020. |
|---|
|
|
O-10. Examination of the risk factor of type I diabetes mellitus with the immune checkpoint inhibitor using JADER 高田慎也, 山岸佳代, 橋下浩紀, 遠藤雅之 Journal of Japanese Society of Pharmaceutical Oncology 15: 140-140, 2020. |
|---|
|
|
O-11. Examination of the usefulness of the PTP sheet pasting type new medication support tool 太田貴洋1,2), 中村真穂1,4), 鈴木真也1), 三輪田徹3), 金子明日美1), 三島沙織4), 小谷大輔4), 谷口浩也4), 坂東英明5), 松井礼子1), 山口正和6), 吉野孝之4), 川崎敏克1) Journal of Japanese Society of Pharmaceutical Oncology 15: 141-141, 2020. |
|---|
|
|
O-12. The chemotherapy-induced neutropenia in patients with extensive-stage small-cell lung cancer and related examination with the survival period 中尾將彦1), 辻大樹2), 宮城壮裕2), 川崎洋平3), 山本圭祐4), 林稔展5), 鮎原秀明6), 中垣繁7), 原田知彦8), 石川寛9), 玉木慎也10), 前田章光11), 大橋養賢12), 宮本康敬13), 荒川雄一朗14), 矢野琢也15), 藤田行代志16), 伊藤邦彦2) Journal of Japanese Society of Pharmaceutical Oncology 15: 142-142, 2020. |
|---|
|
|
O-13. About relations of Infusion reaction expression and the pre-medication at the trastuzumab initial administration in our hospital 島田浩和, 大神正宏, 立原茂樹, 市塚亜由美, 石川洋輔, 小島友恵, 柴このみ, 鈴木美加 Journal of Japanese Society of Pharmaceutical Oncology 15: 143-143, 2020. |
|---|
|
|
O-14. Examination about a risk factor and the treatment continuance of the treatment with eribulin mesilate neutropenia to develop early 鈴木訓史1), 田中寛之2), 村上寛知3), 遠藤雅之2), 後藤達也1) Journal of Japanese Society of Pharmaceutical Oncology 15: 144-144, 2020. |
|---|
|
|
O-15. Than the questionary survey for examination - 622 of the effect that a pharmacist outpatient gives in an understanding degree and psychologic aspect on treatment with anticancer agent ... 西部星来1), 安藤洋介1), 小出菜優1), 平嶋一貴1), 松田日出三1), 辻井奈保1), 柘植雅大1), 河田健司2), 山田成樹1) Journal of Japanese Society of Pharmaceutical Oncology 15: 145-145, 2020. |
|---|
|
|
O-16. Examination of the ARC risk assessment technique in patients with blood-forming organ tumor 齋藤一樹, 神尾咲留未, 伊藤佳奈子, 東敬太, 伊東隆宏, 猪俣結衣, 鈴木訓史, 菅原秀悦, 吉田和美, 阿部憲介, 後藤達也 Journal of Japanese Society of Pharmaceutical Oncology 15: 146-146, 2020. |
|---|
|
|
O-17. Adverse event evaluation of the Enzalutamide gradual dose titration in the castration-resistant prostate cancer 三浦理恵子1), 平畠正樹1), 入江慶1,2), 池末裕明1), 室井延之1), 川喜田睦司3), 橋田亨1) Journal of Japanese Society of Pharmaceutical Oncology 15: 147-147, 2020. |
|---|
|
|
O-18. Effect to give risk factor analysis and effect of treatment of the dermatopathy with the immune checkpoint inhibitor 馬場楓1), 川澄賢司1), 三浦華歩1), 佐野慶行1), 西澤綾2), 川崎敏克1) Journal of Japanese Society of Pharmaceutical Oncology 15: 148-148, 2020. |
|---|
|
|
O-19. Effect on myelosuppression of the total bilirubin high level associated with the obstructive jaundice in the pancreatic cancer GEM+nabPTX therapy 有馬亜希, 平井成和, 増田雅行 Journal of Japanese Society of Pharmaceutical Oncology 15: 149-149, 2020. |
|---|
|
|
O-20. Internal use, effect of the injectable antimicrobial to give to antitumor effect of the nivolumab 貝野裕也1), 北澤文章1), 前野有紀1), 大井隆広1), 坂野玲子1), 中藏伊知郎1), 中村孝人2), 辻川正彦1) Journal of Japanese Society of Pharmaceutical Oncology 15: 150-150, 2020. |
|---|
|
|
O-22. Search of the dangerously ill high TG blood symptom risk factor due to bexarotene administration 森悠香梨1), 真川明将2), 早川智章2), 須藤遥2), 竹本将士2), 堀田祐志1,2), 近藤勝弘2), 木村和哲1,2,3) Journal of Japanese Society of Pharmaceutical Oncology 15: 152-152, 2020. |
|---|
|
|
O-23. Unresectable safety assessment of progress, the recurrent biliary cancer Gemcitabine+Cisplatin therapy of a little fluid replacement load 市村丈典1,2), 縄田修一1,2), 市倉大輔1,2), 臼田昌弘1,2), 木村祐子1,2), 田中茜1,2), 徳永愛美1,2), 渡辺裕貴1,2), 日向美羽1,2), 峯村純子1,2), 佐々木忠徳2) Journal of Japanese Society of Pharmaceutical Oncology 15: 153-153, 2020. |
|---|
|
|
O-24. Examination of the clinical effect that calcium-channel blocker in the ramucirumab + paclitaxel therapy gives 槙原克也, 木本大樹, 松村友和 Journal of Japanese Society of Pharmaceutical Oncology 15: 154-154, 2020. |
|---|
|
|
O-25. Example that caused hyperammonemia after the FOLFIRI therapy for unresectable progress recurrence colon cancer 朝比奈由1), 輿石徹1), 川辺千苗美1), 虎石竜典1), 新後閑正敏2), 小金澤樹2), 横塚慧2), 三吉健太2), 富田晃一2), 日高英二2), 河地茂行2), 吉元公一2) Journal of Japanese Society of Pharmaceutical Oncology 15: 155-155, 2020. |
|---|
|
|
O-26. 1 case of the deep vein thrombosis that CA 19-9 false-positive was thought to cause 内藤雅人1), 鳥居良太1), 橋本佑樹1), 川本雄規2), 林賢一2), 篠田弘昭2), 本城裕美子2), 廣吉基己3) Journal of Japanese Society of Pharmaceutical Oncology 15: 156-156, 2020. |
|---|
|
|
O-27. One patient who received readministration for hypersensitivity patients with oxaliplatin with colon cancer which developed 吉田勝好1), 俵早紀1), 田原明子1), 郷原学1), 篠原由美2), 服部晋司3) Journal of Japanese Society of Pharmaceutical Oncology 15: 157-157, 2020. |
|---|
|
|
O-28. Example that accepted recovery of the thrombocytopenia by administration of Juzentaihoto 新美政樹1), 菊池正和2), 尾畑景子3), 谷口結基1), 森智世1), 田中美帆1), 太田達也1), 田中章郎1) Journal of Japanese Society of Pharmaceutical Oncology 15: 158-158, 2020. |
|---|
|
|
O-29. Use experience of the nalfurafine hydrochloride for the intractable itching due to panitumumab 鳥居良太1), 内藤雅人1), 下雅意彩1), 竹村敏也1), 本城裕美子2) Journal of Japanese Society of Pharmaceutical Oncology 15: 159-159, 2020. |
|---|
|
|
O-30. We look at the rear about the infusion reaction at the daratumumab administration and examine a mark 田代雄祐1), 黒田純子1), 外海友規1), 安村和華1), 飯田真介2), 木村和哲1,3,4) Journal of Japanese Society of Pharmaceutical Oncology 15: 160-160, 2020. |
|---|
|
|
O-31. The incidence of retching in the hepatic artery chemoembolisation and clinical examination of the use of antiemetic 金子奨太1), 吉田謙介1), 鈴木直人1), 坂牧僚2), 外山聡1) Journal of Japanese Society of Pharmaceutical Oncology 15: 161-161, 2020. |
|---|
|
|
O-32. Examination of the patients with neutropenia background factor who come to have a long dosing period of the G-CSF preparation by protraction 冨島公介, 土谷有美, 津田正博 Journal of Japanese Society of Pharmaceutical Oncology 15: 162-162, 2020. |
|---|
|
|
O-33. Examination of the risk factor of the acute renal failure onset in the initial docetaxel + cisplatin + fluorouracil therapy for the cancer of the esophagus 古原優也, 高橋克之, 豕瀬諒, 高橋正也, 永山勝也 Journal of Japanese Society of Pharmaceutical Oncology 15: 163-163, 2020. |
|---|
|
|
O-34. Comparison of the side effect expression situation for R-CHOP therapy, the R-miniCHOP therapy 大野峻, 北島聖也, 武田元樹, 菊池健, 渡邉大毅, 相馬貴史, 佐々木啓, 鶴山辰 Journal of Japanese Society of Pharmaceutical Oncology 15: 164-164, 2020. |
|---|
|
|
O-35. Effect of aprepitant to give Carboplatin-induced hiccups 田島英, 吉澤朝枝, 塩月智子, 玉木美記, 中田耕市 Journal of Japanese Society of Pharmaceutical Oncology 15: 165-165, 2020. |
|---|
|
|
O-36. Examination - multicenter prospective study study - to the regimen confirmation item standardization of the pharmacist concerned with cancer medical therapy 植木大介1), 太田貴洋2), 宇田川涼子3), 鈴木真也4), 大橋養賢2), 龍島靖明5), 小沼大祐6), 元茂拓法7), 家岡昌弘8), 田路章博9), 小暮友毅10), 平池美香子11), 魚井みゆき12), 川崎敏克4), 山口正和3), 稲生和彦1) Journal of Japanese Society of Pharmaceutical Oncology 15: 166-166, 2020. |
|---|
|
|
O-37. Fact-finding of anticancer medicine occupation characteristics exposure measures in Ibaraki 柴このみ, 大神正宏, 立原茂樹, 市塚亜由美, 石川洋輔, 島田浩和, 小島友恵, 鈴木美加 Journal of Japanese Society of Pharmaceutical Oncology 15: 167-167, 2020. |
|---|
|
|
O-38. Examination of preventive measures against anticancer agent exposure to infusor pump 降旗聖子1), 久保由佳1), 森満孝裕1), 高松登1), 谷津直美2), 椎原千鶴2), 野沢佳奈子2), 星野利香2), 中村麻耶2), 大野玲3) Journal of Japanese Society of Pharmaceutical Oncology 15: 168-168, 2020. |
|---|
|
|
O-39. Efforts for the use situation and the proper use of the immune checkpoint inhibitor 大木雅貴1), 中村朗2), 菅谷敏和1), 高木克彦1), 菅谷誠1) Journal of Japanese Society of Pharmaceutical Oncology 15: 169-169, 2020. |
|---|
|
|
O-40. Duties development to medicine medicine cooperation based on the anticoagulant prescription investigation of the patients not to deceive 中村久美1), 三浦篤史1), 鬼窪利英1), 松原重征2), 村田稔弥3), 西瀬直美3), 野村香織4), 馬場麻理子4), 浅野美代子4) Journal of Japanese Society of Pharmaceutical Oncology 15: 170-170, 2020. |
|---|
|
|
O-41. Efforts for the side effect early detection of the immune checkpoint inhibitor in our hospital 近藤雅1), 江尻将之1), 黒瀬優輔1), 春日井悠司1), 岩本慈能2), 池田幸代2), 三嶋秀行2), 築山郁人3), 大西正文1) Journal of Japanese Society of Pharmaceutical Oncology 15: 171-171, 2020. |
|---|
|
|
O-42. Consciousness and cooperation problem for the cancer medical therapy that we investigated in a study session hosted by the pharmacist society in 3 areas 金井貴充, 楠浩子, 伊藤富弘 Journal of Japanese Society of Pharmaceutical Oncology 15: 172-172, 2020. |
|---|
|
|
O-43. Medicine medicine collaboration ... which used telephone follow-up - tracing report for the oral molecular target medicine remedy patients 西垣賢1), 米田勝晃2) Journal of Japanese Society of Pharmaceutical Oncology 15: 173-173, 2020. |
|---|
|
|
O-44. Efforts ... patients interview sheet and red flag signature confirmation vote ... to the immune-mediated adverse event management tool making by the Saitama cancer medical therapy workshop 鈴木栄1), 新井隆広2), 国吉央城3), 鈴木貴之4), 武井大輔5), 野村久祥6), 吉野真樹7), 渡邉裕之8), 中山季昭9), 佐野元彦10) Journal of Japanese Society of Pharmaceutical Oncology 15: 174-174, 2020. |
|---|
|
|
O-45. From the situation of the small health insurance pharmacy that received our problem anticancer medicine instruction contents offer book that it seemed that we looked back on medicine medicine cooperation 高津こずえ, 登坂紀一朗, 秋嶋徹郎 Journal of Japanese Society of Pharmaceutical Oncology 15: 175-175, 2020. |
|---|
|
|
O-46. Decontamination effect of 5-FU with the toilet seat wiper collecting sheet 宮澤憲治1), 大橋彩乃2), 名倉希美2), 八田裕之1), 岡田守弘2) Journal of Japanese Society of Pharmaceutical Oncology 15: 176-176, 2020. |
|---|
|
|
O-47. The holding of the workshop about the regimen management for the hospital pharmacist of Nara and the evaluation 渡邊裕之1), 木村錦子1), 子守晶子2), 樋野光夫3), 高橋克之4), 飯原大稔5), 鎌田宏和6), 橋本浩伸7), 東光久8), 神野正敏9), 辻力夫1) Journal of Japanese Society of Pharmaceutical Oncology 15: 177-177, 2020. |
|---|
|
|
O-48. Examination of the effect to the pharmacy by the SPD trust of anticancer agent logistics 桝茂典, 秋本純矢, 茂原圭佑, 岡田悠美, 中川隼一, 皆川拓也, 蔭山博之, 平島徹 Journal of Japanese Society of Pharmaceutical Oncology 15: 178-178, 2020. |
|---|
|
|
O-49. Medical economic effect by the Drug Vial Optimization (DVO) introduction in the general hospital and inspection of the hospital burden 伊藤剛貴1), 平野航1), 本石寛行1), 木村直也1,2), 源川良一1), 根岸健一2) Journal of Japanese Society of Pharmaceutical Oncology 15: 179-179, 2020. |
|---|
|
|
O-50. It is one patient receiving mirtazapine for the retching control of patients with diabetes 森智世1), 田島万莉2), 尾畑景子3), 新美政樹1), 谷口結基1), 田中美帆1), 太田達也1), 田中章郎1) Journal of Japanese Society of Pharmaceutical Oncology 15: 180-180, 2020. |
|---|
|
|
O-51. 1 case that was able to prevent the seasonal flu infection of the patients during molecular target medicine remedy by a telephone follow-up 藤井康之 Journal of Japanese Society of Pharmaceutical Oncology 15: 181-181, 2020. |
|---|
|
|
O-52. Inspection of the anticancer agent exposure protective efficacy by the use of chemo cover (R) 前岡理利子1), 宮田広樹1), 此松晶子1), 安島亜矢子1), 上森恵里1), 小野寺恵子2), 水澤真由美2), 高橋芙美子2), 笠原英城1) Journal of Japanese Society of Pharmaceutical Oncology 15: 182-182, 2020. |
|---|
|
|
O-53. Fact-finding of the nutritional status using MUST to patients who received foreign chemotherapy in the health insurance pharmacy 山根孝太1), 熊谷岳文2) Journal of Japanese Society of Pharmaceutical Oncology 15: 183-183, 2020. |
|---|
|
|
O-54. Efforts and problem of the pharmacist for the cancer chemotherapy of the local general hospital 戸田宏子1), 三松謙司2), 熊坂美希子3), 白戸美穂3), 岸本裕一4), 藤川博敏5), 大木隆史6), 今井豊1), 當間嗣利1) Journal of Japanese Society of Pharmaceutical Oncology 15: 184-184, 2020. |
|---|
|
|
P-001. Investigation of the use situation of the immune checkpoint inhibitor and the immune-mediated adverse event 宇野健一, 小嶋啓修 Journal of Japanese Society of Pharmaceutical Oncology 15: 185-185, 2020. |
|---|
|
|
P-002. Examination of the factor involved in onset of allergic reaction with the oxaliplatin administration 高山裕樹1), 高山俊輔1), 小谷野大地1), 眞壁秀樹1), 玉木秀子2), 濱口哲弥3), 三原良明3) Journal of Japanese Society of Pharmaceutical Oncology 15: 186-186, 2020. |
|---|
|
|
P-003. We are safe, and is the use of the Ron surf combination lock to patients with old progress, recurrence colon cancer useful? - Inspection - of overall survival and the side effect profile in elderly people 75 years or older 木村美智男, 宇佐美英績, 吉村知哲 Journal of Japanese Society of Pharmaceutical Oncology 15: 187-187, 2020. |
|---|
|
|
P-004. We look at the rear of the onset of hyponatremia situation with the platinum administration and investigate a mark 小川純明1), 佐藤淳也1,2,4), 榊原辰弥1), 田中怜1,3), 篠道弘1) Journal of Japanese Society of Pharmaceutical Oncology 15: 188-188, 2020. |
|---|
|
|
P-005. Examination of the use situation and the adverse event of the Obinutuzumab in our hospital 牛島佳帆里, 久保杏奈, 米澤美和, 山田千代子 Journal of Japanese Society of Pharmaceutical Oncology 15: 189-189, 2020. |
|---|
|
|
P-006. Usefulness of the protein urine creatinine ratio measurement in the ramucirumab 柄沢良恵, 田中祐介, 堀越慶一, 福元剛 Journal of Japanese Society of Pharmaceutical Oncology 15: 190-190, 2020. |
|---|
|
|
P-007. Effect on renal function accompanied with the short hydration shift in the urothelial carcinoma GC therapy 古舘晶弘, 平井成和, 土井啓員, 佐野君芳, 増田雅行 Journal of Japanese Society of Pharmaceutical Oncology 15: 191-191, 2020. |
|---|
|
|
P-008. Effect ... to give the informed choice of evaluation ... patients of the pharmacist explanation at taxane drugs choice after the breast cancer AC therapy 田畑真一1), 戸塚孝治1), 長岡弘2), 新井成俊1) Journal of Japanese Society of Pharmaceutical Oncology 15: 192-192, 2020. |
|---|
|
|
P-009. Search of the factor having an influence on the rise in D-dimer value after the Bevacizumab administration in patients with unresectable progress recurrence colon cancer 遠藤篤, 石井直人, 小村裕子 Journal of Japanese Society of Pharmaceutical Oncology 15: 193-193, 2020. |
|---|
|
|
P-010. Efforts of by medical examination front for oral anticancer medicine-treated patients in the outpatient department and the evaluation 藤村拓也1), 畑賢太1), 斉藤俊英1), 神垣輝美1), 相馬まゆ子1), 佐々木洋一1), 今田愛也2), 山本浩史1) Journal of Japanese Society of Pharmaceutical Oncology 15: 194-194, 2020. |
|---|
|
|
P-011. customer satisfaction assay of the original nutrition table which we made for the oral anticancer medicine remedy patients 川地志緒里, 郷真貴子, 西村充礼, 宇佐美英績, 木村美智男, 吉村知哲 Journal of Japanese Society of Pharmaceutical Oncology 15: 195-195, 2020. |
|---|
|
|
P-012. The development of heart disorder situation investigation with the sequential administration of epirubicin and the trastuzumab 萬浪綾乃, 明石直子, 足立紗知, 篠原莉奈, 大谷陽子, 水谷麻紀子, 八十島宏行, 宮部貴識, 佐光留美, 増田慎三, 山内一恭 Journal of Japanese Society of Pharmaceutical Oncology 15: 196-196, 2020. |
|---|
|
|
P-013. The current situation investigation of the antiemesis therapy for the oral risk molecules target medicine emetic more than moderate degree in our hospital 熊谷康平, 畑裕基, 中野一也, 山下大輔, 別府博仁, 本田芳久 Journal of Japanese Society of Pharmaceutical Oncology 15: 197-197, 2020. |
|---|
|
|
P-014. Fact-finding of the edematous expression in the docetaxel 後藤孝之1), 鈴木博1), 井上朋子1), 亀井陽子1), 佐竹清1), 町田充1), 斎藤毅2) Journal of Japanese Society of Pharmaceutical Oncology 15: 198-198, 2020. |
|---|
|
|
P-015. The effect that medication counseling of the mouth care by the pharmacist gives in oral mucositis and the eating of patients with cancer 田中雄介, 吉田謙介, 鈴木直人, 外山聡 Journal of Japanese Society of Pharmaceutical Oncology 15: 199-199, 2020. |
|---|
|
|
P-016. Examination about the effectiveness and the side effect of the Lenvatinib for the unresectable hepatocellular carcinoma 江原美里, 宮城和代, 宮部貴識, 佐光留美, 山内一恭 Journal of Japanese Society of Pharmaceutical Oncology 15: 200-200, 2020. |
|---|
|
|
P-017. Examination of the effect that a concomitant drug with an immunomodulation effect gives for the effect of the immune checkpoint inhibitor 三浦華歩1,3), 佐野慶行1), 川澄賢司1), 望月伸夫1), 仁保誠治2), 後藤功一2), 川崎敏克1), 花田和彦3) Journal of Japanese Society of Pharmaceutical Oncology 15: 201-201, 2020. |
|---|
|
|
P-019. Adverse event investigation comparison of the Lenvatinib in hepatocytes cancer by the difference in liver spare usability test classification 東修司1), 中田絵梨1), 坂本華代1), 嘉屋則子1), 稲垣育宏1), 田畑裕和1), 小寺隆二1), 柴波明男1), 本田宗也2), 斎藤義徳2) Journal of Japanese Society of Pharmaceutical Oncology 15: 203-203, 2020. |
|---|
|
|
P-020. The search of the risk factor of the onset of Colin symptom with irinotecan and relative examination with the tardive diarrhea 祖父江伸匡1), 橋本拓郎1), 川嵜真太郎1), 綺田尚久1), 堀敦雄1), 藤原信二1), 塩見尚礼2), 西嶋長1) Journal of Japanese Society of Pharmaceutical Oncology 15: 204-204, 2020. |
|---|
|
|
P-021. Role of the genome charge pharmacist in the Kyushu cancer center cancer genomic medicine system 衛藤智章1,2), 高崎紘臣1,2), 田中麻紀子1,2), 松元俊博1,2), 松谷奈央1), 井手尾里美1), 薦田正人3), 織田信弥1), 江崎泰斗1,3) Journal of Japanese Society of Pharmaceutical Oncology 15: 205-205, 2020. |
|---|
|
|
P-022. Evaluation of the expression situation of the immune-mediated adverse event in the cancer special hospital and the measures 新井隆広1), 荒木和浩2), 長澤侑季1), 松本弘恵3), 山崎美穂3), 藤田行代志1), 齊藤妙子1) Journal of Japanese Society of Pharmaceutical Oncology 15: 206-206, 2020. |
|---|
|
|
P-023. As rituximab BS pre-medication in the Kitami Red Cross hospital an investigation about the expression of response (IRR) and the sleepiness accompanied with the infusion at the Bilastine administration 木村彩那1), 安藤寿典1), 富田浩史1), 佐藤友昭1), 筒井道彰1), 堀大1), 國井みすず2), 永嶋貴博3) Journal of Japanese Society of Pharmaceutical Oncology 15: 207-207, 2020. |
|---|
|
|
P-024. Examination of the effect that a change of the gut flora gives for the effect of treatment of the immune checkpoint inhibitor 東敬太, 齋藤一樹, 伊藤佳奈子, 鈴木訓史, 後藤達也 Journal of Japanese Society of Pharmaceutical Oncology 15: 208-208, 2020. |
|---|
|
|
P-025. PK/PD model analysis of the neutropenia of the docetaxel + ramucirumab combination therapy in patients with non-small cell lung cancer 細見周平1), 入江慶1,2), 平畠正樹1), 池末裕明1), 室井延之1), 佐藤悠城3), 富井啓介3), 橋田亨1) Journal of Japanese Society of Pharmaceutical Oncology 15: 209-209, 2020. |
|---|
|
|
P-026. Oral anticancer agent confirmation is foreign: About a physician and the usefulness of conducting prior consultation 小林加奈1), 坂本充司1), 濱口智亘1), 鎌田和代1), 倉立真志2) Journal of Japanese Society of Pharmaceutical Oncology 15: 210-210, 2020. |
|---|
|
|
P-027. Association with the high blood pressure that occurred after the castration acquisition of fastness and the hormonal therapies in the prostate cancer 林友典1), 宮本朋佳2), 松岡寛1), 川畑篤史3) Journal of Japanese Society of Pharmaceutical Oncology 15: 211-211, 2020. |
|---|
|
|
P-028. Fact-finding of consultation, the treatment situation at the checkpoint inhibitor-related adverse event (irAE) expression of immunity 吉田弘樹1), 鈴木雅人1), 高原悠子1), 三屋良太1), 牧原明秀1), 木全司1), 松浦美聡2), 石間伏由紀2) Journal of Japanese Society of Pharmaceutical Oncology 15: 212-212, 2020. |
|---|
|
|
P-030. The use situation of the naldemedine in our hospital 松島静香, 鳥山陽子, 谷口潤, 尾之江剛樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 213-213, 2020. |
|---|
|
|
P-031. Comparison of the onset of impaired renal function by the presence or absence of magnesium supplement in the cisplatin divided doses regimen 仮屋洋佑1), 橋詰淳哉1), 宮永圭1), 川原和也2), 伊藤直子1), 小山直子1), 神田紘介1), 兒玉幸修1), 中村忠博1), 坂口功一3), 佐々木均1), 室高広1) Journal of Japanese Society of Pharmaceutical Oncology 15: 214-214, 2020. |
|---|
|
|
P-032. Comparison of the antiemesis effect before and after the antiemetic change in the cisplatin divided doses regimen 小山直子1), 橋詰淳也1), 伊藤直子1), 宮永圭1), 仮屋洋佑1), 神田紘介1), 兒玉幸修1), 中村忠博1), 坂口功一2), 佐々木均1), 室高広1) Journal of Japanese Society of Pharmaceutical Oncology 15: 215-215, 2020. |
|---|
|
|
P-033. Operation and evaluation of the side effect monitoring in the immune checkpoint inhibitor 井筒理子, 宮川貴行, 梶井孝洋, 西澤修一, 大倉裕祐 Journal of Japanese Society of Pharmaceutical Oncology 15: 216-216, 2020. |
|---|
|
|
P-034. Examination of the side effect expression of nivolumab change in the dose change 岩切悦子, 難波優希, 小玉美希子, 水津智樹, 辰己晃造, 畝佳子, 政道修二 Journal of Japanese Society of Pharmaceutical Oncology 15: 217-217, 2020. |
|---|
|
|
P-036. Evaluation of the blood level of the methotrexate in the presence or absence of proton pump inhibitor combination 森健太郎, 大谷寧次郎, 畔柳敏弥 Journal of Japanese Society of Pharmaceutical Oncology 15: 218-218, 2020. |
|---|
|
|
P-037. Enforcement of by pharmacist medical examination front in the Abemaciclib remedy patients and the result 玉木慎也, 長谷川遥, 田初夏苗, 遠藤雅之 Journal of Japanese Society of Pharmaceutical Oncology 15: 219-219, 2020. |
|---|
|
|
P-038. About the expression situation of the neutropenia in trifluridine Tipiracil hydrochloride treated patients and association with renal function and the age 山村真貴子, 沖田健太郎, 長谷川将, 安河内寿成, 白石貴寿, 中村泰士 Journal of Japanese Society of Pharmaceutical Oncology 15: 220-220, 2020. |
|---|
|
|
P-039. The use of checkpoint inhibitor situation in the non-small cell lung cancer of immunity and immune-mediated adverse event expression situation investigation 高橋慎太郎, 三浦宏真, 菊池亮大, 小柳佑司, 三浦清彦 Journal of Japanese Society of Pharmaceutical Oncology 15: 221-221, 2020. |
|---|
|
|
P-040. Comparison of the adverse event in the ramucirumab + paclitaxel for the progress gastric cancer or albumin suspension type paclitaxel therapy 鈴木実, 北條文啓, 岩上泰崇, 佐久間淳一 Journal of Japanese Society of Pharmaceutical Oncology 15: 222-222, 2020. |
|---|
|
|
P-041. Examination of all medication at the trastuzumab administration 松本千明1), 藤野尚子1), 竹元信之2) Journal of Japanese Society of Pharmaceutical Oncology 15: 223-223, 2020. |
|---|
|
|
P-042. Investigation of the foreign cancer chemotherapy cancellation reason in the municipal Nagahama Hospital 西増春佳, 中村俊之, 大岡千寿子, 野洌孝二, 小室太郎 Journal of Japanese Society of Pharmaceutical Oncology 15: 224-224, 2020. |
|---|
|
|
P-043. Search of the factor affecting the side effect expression of Lenvatinib in patients with hepatocellular carcinoma 望月暁, 熊野光翼, 上田桂子, 安藤寛子, 猪瀬成史, 堀越建一 Journal of Japanese Society of Pharmaceutical Oncology 15: 225-225, 2020. |
|---|
|
|
P-044. Examination about infusion reaction measures of the Obinutuzumab 坂本竜平1), 向井淳治1,2), 小竹優希1), 竹原涼子1), 濱崎淳哉1), 奥田広志1) Journal of Japanese Society of Pharmaceutical Oncology 15: 226-226, 2020. |
|---|
|
|
P-046. We look at the rear about the diarrhea during uterine cervix cancer concurrent chemoradiotherapy and investigate a mark 羽田真理子, 廣井順子 Journal of Japanese Society of Pharmaceutical Oncology 15: 228-228, 2020. |
|---|
|
|
P-047. Examination about the adverse event of the Durvalumab 小竹優希1), 向井淳治1,2), 坂本竜平1), 竹原涼子1), 濱崎淳哉1), 奥田広志1) Journal of Japanese Society of Pharmaceutical Oncology 15: 229-229, 2020. |
|---|
|
|
P-048. We look at the rear about the neutropenia by the combination of albumin suspension type paclitaxel and clopidogrel and examine a mark 石森雅人, 畠山朋樹, 佐藤麻理, 松本光司, 福田稔 Journal of Japanese Society of Pharmaceutical Oncology 15: 230-230, 2020. |
|---|
|
|
P-049. 1 case that suffered from venous thrombosis during FOLFIRI+Bevacizumab administration 山田憲和1), 山本康代2), 酒井恵子2), 齊藤康子3), 後藤拓也4), 佐々木久5) Journal of Japanese Society of Pharmaceutical Oncology 15: 231-231, 2020. |
|---|
|
|
P-050. The use situation of the Lenvatinib capsule in our hospital 天野正康, 鈴木諒, 桑原健太, 富田歩子 Journal of Japanese Society of Pharmaceutical Oncology 15: 232-232, 2020. |
|---|
|
|
P-051. Effective examination of the butylscopolamine coinfusion for the prevention of the irinotecan-induced Colin symptom 山口竜司, 樋口美奈子, 佐々木好美, 和田依子, 児玉沙奈恵 Journal of Japanese Society of Pharmaceutical Oncology 15: 233-233, 2020. |
|---|
|
|
P-052. 2 cases that produced hyperammonemia by systemic chemotherapy containing 5-FU 小林和博, 近藤篤, 三宅麻文, 尾上雅英 Journal of Japanese Society of Pharmaceutical Oncology 15: 234-234, 2020. |
|---|
|
|
P-053. An example of the super old non-small cell lung cancer which started Osimertinib under the electrocardiogram monitor surveillance 河本怜史, 香取哲哉, 青柳友彦, 木村敦, 出雲貴文 Journal of Japanese Society of Pharmaceutical Oncology 15: 235-235, 2020. |
|---|
|
|
P-054. 1 case that utilized a cooperation tool, and contributed to treatment of the severe dermatopathy with Nivolumab 田中和行, 三村奈美子, 脇本友絵, 渡辺美和 Journal of Japanese Society of Pharmaceutical Oncology 15: 236-236, 2020. |
|---|
|
|
P-055. Examination about treatment continuity of azacitidine in the true clinical practice and the effect 宇佐美英績, 木村美智男, 竹中翔也, 吉村知哲 Journal of Japanese Society of Pharmaceutical Oncology 15: 237-237, 2020. |
|---|
|
|
P-057. 1 case that acute renal failure developed by methotrexate administration in large quantities and dialyzed 陣内優, 畑瀬圭佐, 有冨航平 Journal of Japanese Society of Pharmaceutical Oncology 15: 239-239, 2020. |
|---|
|
|
P-058. Case report about two MSI-High solid cancer which we experienced in our hospital 佐藤数馬1), 稲本正之1), 香月優亮2), 櫻井嘉彦2), 大谷亨1) Journal of Japanese Society of Pharmaceutical Oncology 15: 240-240, 2020. |
|---|
|
|
P-059. Examination of the preoperation DDMVAC therapy for the muscle-invasive bladder cancer 香取哲哉1), 青柳友彦1), 木村敦1), 河本怜史1), 出雲貴文1), 久末伸一2) Journal of Japanese Society of Pharmaceutical Oncology 15: 241-241, 2020. |
|---|
|
|
P-060. One patient who learned the difficulty of the cancer pain evaluation 渡邊利栄, 光明麗 Journal of Japanese Society of Pharmaceutical Oncology 15: 242-242, 2020. |
|---|
|
|
P-061. Protective efficacy of chemotherapy-induced retching, vomiting with olanzapine 丹下信孝1), 今城宏文1), 古川卓也2), 関野陽子2) Journal of Japanese Society of Pharmaceutical Oncology 15: 243-243, 2020. |
|---|
|
|
P-062. One case in acknowledgment of seasonal polymorphism exudativa rash - Stevens Johnson's syndrome systemic in Osimertinib of the EGFR mutation in the gene-positive non-small cell lung cancer 中野恵理子1,2), 藤宮龍祥1,2), 宮本渚2), 香川恭子2), 武井華子3), 中田土起丈3), 藤嶋彬4), 鹿間裕介4), 田中広紀1,2), 渡邊徹1,2), 佐々木忠徳1) Journal of Japanese Society of Pharmaceutical Oncology 15: 244-244, 2020. |
|---|
|
|
P-063. 1 case that existing psoriasis worsened after the Pembrolizumab administration for urothelial carcinoma 吉村芙美, 宮城和代, 明石直子, 宮部貴識, 佐光留美, 山内一恭 Journal of Japanese Society of Pharmaceutical Oncology 15: 245-245, 2020. |
|---|
|
|
P-064. One patient who showed a rise of the procalcitonin by Obinutuzumab administration 喜多聖1), 宮田恵里2), 市川和幸1), 中西伸樹1), 佐久間隆幸1), 中村昭宣1) Journal of Japanese Society of Pharmaceutical Oncology 15: 246-246, 2020. |
|---|
|
|
P-065. Example that presented remarkable neutropenia after FOLFIRI start for colon cancer 尾又玲伊, 角谷直志, 武田元樹, 菊池健, 渡邉大毅, 佐々木啓, 相馬貴史, 鶴山辰 Journal of Japanese Society of Pharmaceutical Oncology 15: 247-247, 2020. |
|---|
|
|
P-066. The administration number of patients and the irAE expression situation of the immune checkpoint inhibitor in our hospital 友利幹夫1), 宮城琢1), 上原淳奈1), 比嘉綾子1), 川平浩子1), 前森里美2) Journal of Japanese Society of Pharmaceutical Oncology 15: 248-248, 2020. |
|---|
|
|
P-067. An example of the pharmaceutical intervention for the low Mg blood symptom in patients in CKD during panitumumab administration 伊佐治麻里子, 桑山果織, 白井博 Journal of Japanese Society of Pharmaceutical Oncology 15: 249-249, 2020. |
|---|
|
|
P-068. 1 case that caused a decreased renal function after the Abemaciclib start 吉川里香1), 福嶋浩一1), 田村昌三1), 奥野昌宏1), 三瀬昌弘2), 田中詳二1) Journal of Japanese Society of Pharmaceutical Oncology 15: 250-250, 2020. |
|---|
|
|
P-069. The situation of the use actual situation and the pharmacist intervention of the Abemaciclib in our hospital 渡邉貴子1), 清美奈1), 殿村直也1), 三浦裕馬1), 石原溶子1), 有賀智之2) Journal of Japanese Society of Pharmaceutical Oncology 15: 251-251, 2020. |
|---|
|
|
P-070. 2 cases with suspected onset of type I diabetes mellitus by the nivolumab 浦田修平1), 大野梨絵1), 上野浩晶2), 田崎智也1), 千阪智美1), 平原康寿1), 池田龍二1) Journal of Japanese Society of Pharmaceutical Oncology 15: 252-252, 2020. |
|---|
|
|
P-071. One case that came by an at-home shift by octreotide sustained administration using HOMEPOMP C-SERIES(R) for intractable ileus 津田優里香, 高木明子, 川合沙季, 高本裕子, 芳本尚, 長島裕樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 253-253, 2020. |
|---|
|
|
P-072. The use actual situation of the immune checkpoint inhibitor in our hospital 青木祥子, 佐藤康, 石塚ほから, 樋口貴子, 市川友莉恵, 佐藤宏 Journal of Japanese Society of Pharmaceutical Oncology 15: 254-254, 2020. |
|---|
|
|
P-074. Use fact-finding of the hydromorphone hydrochloride in our hospital 清水彩加, 仲野宏紀, 明石直子, 宮部貴識, 佐光留美, 山内一恭 Journal of Japanese Society of Pharmaceutical Oncology 15: 256-256, 2020. |
|---|
|
|
P-075. Comparison of the hand-and-foot syndrome protective efficacy by the capecitabine of OTC medicine and the prescribed medicine 前原央奈1), 角佳亮2) Journal of Japanese Society of Pharmaceutical Oncology 15: 257-257, 2020. |
|---|
|
|
P-076. One patient whom autoimmune myositis developed in during pemetrexed + bevacizumab (maintenance therapy) treatment 松本諭1), 堀部正記1), 遊見裕子1), 杉本啓介2) Journal of Japanese Society of Pharmaceutical Oncology 15: 258-258, 2020. |
|---|
|
|
P-077. One case of the non-small cell lung cancer that we develop a hemophagocytic syndrome by single dose of Atezolizumab, and antitumor effect continues more than one year 堀部正記1), 松本諭1), 遊見裕子1), 杉本啓介2) Journal of Japanese Society of Pharmaceutical Oncology 15: 259-259, 2020. |
|---|
|
|
P-078. 2 cases that developed immune thrombocytopenia after Atezolizumab administration for non-small cell lung cancer 福岡麻実, 山本泰大, 福岡智宏, 近藤綾子, 宇都宮純平 Journal of Japanese Society of Pharmaceutical Oncology 15: 260-260, 2020. |
|---|
|
|
P-079. 1 case that suffered from a cause evaluation of retching during treatment with anticancer agent 吉見倫枝1), 市川和哉1), 西村正2), 内藤雅大2), 井端英憲2), 阿部康治1) Journal of Japanese Society of Pharmaceutical Oncology 15: 261-261, 2020. |
|---|
|
|
P-080. One patient who received DLd therapy by adjusting rate of application for the heart amyloidosis patients 比嘉大輔, 永井賢作, 金城雄一 Journal of Japanese Society of Pharmaceutical Oncology 15: 262-262, 2020. |
|---|
|
|
P-081. 1 case that produced colitis after the adrenal insufficiency onset by Pembrolizumab, and was relieved 吉橋諒, 中田和宏, 羽田竜也, 本田隼人, 齊藤美希, 木村美由喜 Journal of Japanese Society of Pharmaceutical Oncology 15: 263-263, 2020. |
|---|
|
|
P-082. Examination about the way of the medication management by the pharmacist whom patients with cancer find 神隆浩1), 阿蘇拡樹1), 野口宣之1), 富岡佳久2), 佐藤秀昭3) Journal of Japanese Society of Pharmaceutical Oncology 15: 264-264, 2020. |
|---|
|
|
P-083. The situation and problem of fact-finding (1) medicine medicine cooperation of the pharmacist intervention about cancer treatment for JASPO health insurance pharmacy members and the cooperation with the medical institution 林啓文1,10), 丹原由希2,10), 村田勇人2,10), 川澄賢司3,10), 堤大輔4,10), 脇本麻美5,10), 中田千博3,10), 河野友昭6,10), 花香淳一7,10), 櫻井洋臣8,10), 濃沼政美9,10), 近藤直樹5,10) Journal of Japanese Society of Pharmaceutical Oncology 15: 265-265, 2020. |
|---|
|
|
P-084. Intervention of the pharmacist to fact-finding (2) outpatient department cancer chemotherapy patients of the pharmacist intervention about cancer treatment for JASPO health insurance pharmacy members 丹原由希1,10), 村田勇人1,10), 林啓文2,10), 川澄賢司3,10), 堤大輔4,10), 脇本麻美5,10), 中田千博3,10), 河野友昭6,10), 花香淳一7,10), 櫻井洋臣8,10), 近藤直樹5,10), 濃沼政美9,10) Journal of Japanese Society of Pharmaceutical Oncology 15: 266-266, 2020. |
|---|
|
|
P-085. Grasp and analysis of the needs for the patients salon in the Ashikaga Red Cross hospital 久間田佳彦1), 雨笠愛実1), 遠藤美貴子2), 邉見光利1) Journal of Japanese Society of Pharmaceutical Oncology 15: 267-267, 2020. |
|---|
|
|
P-086. About the usefulness of the exposure reduction measures - PTP multifunctional label at use of cyclophosphamide tablets - 岡田奈緒1), 大江理菜1), 清水章弘2), 高見陽一郎3), 江川孝4), 島田憲一1) Journal of Japanese Society of Pharmaceutical Oncology 15: 268-268, 2020. |
|---|
|
|
P-087. The current situation of the bone density measurement in the aromatase inhibitor remedy patients 渡辺富美子, 下村直樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 269-269, 2020. |
|---|
|
|
P-088. Anticancer agent germfree preparation remote inspection system introduction and duties improvement effect using a commercial webcam 合田明博1), 永野耕成2), 益田宏代1), 永井海舟1), 有嶋祐未1), 田中和子1) Journal of Japanese Society of Pharmaceutical Oncology 15: 270-270, 2020. |
|---|
|
|
P-089. Making of the anticancer agent preparation sheet using Microsoft Excel 東島幸道, 尾崎紗緒理, 飯田優美, 佐澤卓哉, 吉本有里, 大坪輝行, 伊南裕子, 山脇一浩 Journal of Japanese Society of Pharmaceutical Oncology 15: 271-271, 2020. |
|---|
|
|
P-090. Examination of the decontamination effect of the cyclophosphamide (CPA) using the faintly acid electrolysis water (perception F water (R)) 中石真由美1,2), 中西弘和1) Journal of Japanese Society of Pharmaceutical Oncology 15: 272-272, 2020. |
|---|
|
|
P-091. Examination of the disposal of 440 mg of trastuzumab preparation cost cut by the introduction 中村暢彦1), 一島知樹2), 武田智子2), 長谷川晃司2), 矢野義孝1), 楠本正明1) Journal of Japanese Society of Pharmaceutical Oncology 15: 273-273, 2020. |
|---|
|
|
P-092. An intervention effect to the electrocardiogram enforcement situation confirmation by the pharmacist in Osimertinib treated patients and examination of the usefulness 東川万里子1), 水野貴仁1), 堀田磨理1), 小崎耕自1), 木村智樹2), 山田哲也1) Journal of Japanese Society of Pharmaceutical Oncology 15: 274-274, 2020. |
|---|
|
|
P-093. About the anticancer agent exposure investigation - preparation in the closed system anesthesia drug transportation system (CSTD)-free institution and exposure to administration environment situation - 羽賀博昭1), 上村賢介1), 高橋由美2), 村木彩佳2), 田邊佳奈子2), 和田朋海1), 内坪誉歳1), 武者信行3) Journal of Japanese Society of Pharmaceutical Oncology 15: 275-275, 2020. |
|---|
|
|
P-094. It is ... mainly on evaluation and problem - oral anticancer medicine of the hepatitis B marker check system which we implemented in an electronic chart 鈴木雅人, 高原悠子, 三屋良太, 牧原明秀, 吉田弘樹, 木全司 Journal of Japanese Society of Pharmaceutical Oncology 15: 276-276, 2020. |
|---|
|
|
P-095. Investigation of the exposure situation with the anticancer medicine after the new hospital move 米澤美和, 久保杏奈, 吉田正暢, 山田千代子 Journal of Japanese Society of Pharmaceutical Oncology 15: 277-277, 2020. |
|---|
|
|
P-096. Fact-finding in the chemotherapy regimen inspection of the anticancer agent preparation room 植田茉梨絵1), 稲野寛1), 佐々木寿子1), 田村和敬1), 厚田幸一郎2) Journal of Japanese Society of Pharmaceutical Oncology 15: 278-278, 2020. |
|---|
|
|
P-097. Efforts to the qualitative improvement, standardization of the regimen check in the cancer medical therapy 小田薫, 門田佳子, 今井洋志 Journal of Japanese Society of Pharmaceutical Oncology 15: 279-279, 2020. |
|---|
|
|
P-098. After the investigation and the examination S-1 stomach cancer technique about the revision of the serum creatinine level measured by enzyme method about adjuvant chemotherapy 中澤紘, 藤田瑛, 宮川真波, 新津京介, 木村正彦, 鈴木栄, 長谷部忠史 Journal of Japanese Society of Pharmaceutical Oncology 15: 280-280, 2020. |
|---|
|
|
P-099. Tuberculosis screening before the anticancer agent administration 常友友紀 Journal of Japanese Society of Pharmaceutical Oncology 15: 281-281, 2020. |
|---|
|
|
P-100. Examination of the Drug Vial Optimization (DVO) introduction for the quantity of injectable anticancer agent disposal reduction 秋山恵里佳1), 徳留章1,2), 井尾剛士1), 佐藤仁昭1), 武田清孝1) Journal of Japanese Society of Pharmaceutical Oncology 15: 282-282, 2020. |
|---|
|
|
P-101. About the relation pharmacist to HBV reactivation measures at the cancer chemotherapy 水谷大輝, 正木知宏, 阿萬明, 橋本秀一 Journal of Japanese Society of Pharmaceutical Oncology 15: 283-283, 2020. |
|---|
|
|
P-102. Efforts to the exposure to anticancer agent measures based on the environmental monitoring 生田侑子, 米北浩人, 藤田淳志, 長田悠子, 篠原麻里乃, 中村英治 Journal of Japanese Society of Pharmaceutical Oncology 15: 284-284, 2020. |
|---|
|
|
P-103. Examination of the cost effectiveness in exposure measures by the closed system anesthesia drug transportation system full-scale introduction 小笹英祐, 計良貴之, 秋山七海, 竹端琴美, 圓山絵理, 湊川紘子, 田中恒明 Journal of Japanese Society of Pharmaceutical Oncology 15: 285-285, 2020. |
|---|
|
|
P-104. The current situation and efforts about the HBV reactivation measures in patients who received foreign chemotherapy in our hospital 神垣輝美1), 畑賢太1), 斉藤俊英1), 藤村拓也1), 相馬まゆ子1), 佐々木洋一1), 今田愛也2), 山本浩史1) Journal of Japanese Society of Pharmaceutical Oncology 15: 286-286, 2020. |
|---|
|
|
P-105. About an evaluation after making and the operation of the drug interactions confirmation tool 今野慶一 Journal of Japanese Society of Pharmaceutical Oncology 15: 287-287, 2020. |
|---|
|
|
P-106. Development of the medication reporting book using the database 水井亮1), 村橋憲2), 溝越智広3), 加藤隆幸4), 中里健志5), 国吉央城5), 土屋裕伴5), 加藤聡1) Journal of Japanese Society of Pharmaceutical Oncology 15: 288-288, 2020. |
|---|
|
|
P-107. 1 case that utilized hospital electronic chart information at a health insurance pharmacy, and was given intervention by the medicine medicine cooperation 佐藤由美1), 井上裕貴2) Journal of Japanese Society of Pharmaceutical Oncology 15: 289-289, 2020. |
|---|
|
|
P-108. Efforts of the reporting by the tracing report of the cancer special hospital door front drugstore 照屋千津子, 野々原育子, 土橋美和, 渡邊新二 Journal of Japanese Society of Pharmaceutical Oncology 15: 290-290, 2020. |
|---|
|
|
P-109. Usefulness investigation of the medication support that combined a tracing report with the telephone support for the Lenvatinib remedy patients by the drugstore pharmacist 加藤博昭, 穂積利恵, 石川遥介, 久田健登, 山田祐次, 小鷹篤, 亀山俊 Journal of Japanese Society of Pharmaceutical Oncology 15: 291-291, 2020. |
|---|
|
|
P-110. Examination of the effect that regimen information, indication of the clinical test value give for ethical pharmacy duties on outside Parliament prescription 川口文誉, 常木隆史, 金子憲太郎, 川村僚一朗, 土井路子 Journal of Japanese Society of Pharmaceutical Oncology 15: 292-292, 2020. |
|---|
|
|
P-112. It is questionary survey about the efforts to becoming it oral anticancer agent outside Parliament prescription 平野航, 伊藤剛貴, 木村直也, 源川良一 Journal of Japanese Society of Pharmaceutical Oncology 15: 294-294, 2020. |
|---|
|
|
P-113. Efforts of the role playing workshop for medication counseling unification in the foreign chemotherapy 増野貴司1), 中山和彦1), 塩野智則2), 倉林美里1), 桜沢千世1), 堀口裕之1), 小幡輝夫1) Journal of Japanese Society of Pharmaceutical Oncology 15: 295-295, 2020. |
|---|
|
|
P-114. Intervention investigation of by medical examination front in our hospital 加藤貴由, 遠藤秀竜, 中島彩子, 見尾谷昇, 林彩矢香, 山崎崇 Journal of Japanese Society of Pharmaceutical Oncology 15: 296-296, 2020. |
|---|
|
|
P-115. Efforts of the medicine medicine cooperation using the medicine notebook seal in the foreign cancer chemotherapy 齊藤達也, 高橋郷, 田畑信悟, 佐野宏賢, 瀬川誠, 澤井孝夫 Journal of Japanese Society of Pharmaceutical Oncology 15: 297-297, 2020. |
|---|
|
|
P-116. Insurance pharmacist Hospital training program in Juntendo Clinic attached to the Juntendo University faculty of medicine 佐野阿耶, 齋藤智之, 齊藤有希, 岩川悟, 佐藤邦義, 荒川隆太郎 Journal of Japanese Society of Pharmaceutical Oncology 15: 298-298, 2020. |
|---|
|
|
P-117. Efforts of the early correspondence to a side effect symptom of the capecitabine which utilized PBPM with the health insurance pharmacy 武田智子1), 中村暢彦2), 村上育子3), 佐村頼寿4), 佐野由美子5), 蓑輪圭一郎6), 秋葉由華7), 海野憲郎8), 福本知明9), 藤澤達史10), 芦田真紀11), 藤坂英史12), 梅垣眞由美13), 森津宏紀14), 春名康裕1), 東碧1), 一島知樹1), 関奈緒子1), 川勝勇樹1), 長谷川晃司1) Journal of Japanese Society of Pharmaceutical Oncology 15: 299-299, 2020. |
|---|
|
|
P-118. Competitive review of the examination rate of use before and after the in-hospital immune therapy cooperation manual preparation 野田拓誠1), 畑裕基1), 中野一也1), 別府博仁1), 山下大輔1), 本田芳久1), 宇良敬2) Journal of Japanese Society of Pharmaceutical Oncology 15: 300-300, 2020. |
|---|
|
|
P-119. Investigation of the effect by the adoption change of the pressurized infusion instruments 高木俊輝1), 小原みずき2), 山口圭太郎3), 高橋浩子4), 梶原徹1), 宇都直哉1) Journal of Japanese Society of Pharmaceutical Oncology 15: 301-301, 2020. |
|---|
|
|
P-120. Efforts to the benzodiazepine receptor agonist consumption decrease in patients with cancer 橋本未雷1), 松藤敬佑1), 薮内由里香1), 池田澪樺1), 松元俊博1), 三角紳博1), 西嶋智洋2) Journal of Japanese Society of Pharmaceutical Oncology 15: 302-302, 2020. |
|---|
|
|
P-121. Questionnaire report - about usefulness - second report patients satisfaction of the appearance care at the health insurance pharmacy that cooperated with the welfare law of nature beautician 田川このみ1), 芝田葵1), 松田枝里1), 岩岡ひとみ4), 丹原由希1), 村田勇人2), 宮原克明3) Journal of Japanese Society of Pharmaceutical Oncology 15: 303-303, 2020. |
|---|
|
|
P-122. The effect that adaptation addition gives for cancer chemotherapy preparation duties on non-small cell lung cancer of the immune checkpoint inhibitor 森元能仁1), 稲野寛2), 長澤知徳3), 尾崎正隆3), 臼井浩明3), 田村勝彦3), 吉田正3), 厚田幸一郎2,4), 篠原高雄3), 渡部一宏1), 廣原正宜1) Journal of Japanese Society of Pharmaceutical Oncology 15: 304-304, 2020. |
|---|
|
|
P-123. The use situation of the hydromorphone hydrochloride extended-release in our hospital 黒木あかね, 高木茂実, 林みどり Journal of Japanese Society of Pharmaceutical Oncology 15: 305-305, 2020. |
|---|
|
|
P-124. Use situation investigation of the Linaclotide for the opioid-induced constipation in our hospital 仲野宏紀1,2), 明石直子1,2), 井出恭子2), 相木佐代2), 清水彩加1,2), 宮城和代1), 田中美早1), 宮部貴識1,2), 佐光留美1), 山内一恭1) Journal of Japanese Society of Pharmaceutical Oncology 15: 306-306, 2020. |
|---|
|
|
P-125. Effect on 5-FU examination by the current situation investigation after the DVO introduction and the introduction expansion 山田将悟, 鈴木直哉, 朝倉幹己, 藤田果那, 田中耕太, 庄崎沙耶, 木下愛, 山本翔太, 前川英輝, 菊地義明, 藤林遼, 高橋誠, 青田忠博 Journal of Japanese Society of Pharmaceutical Oncology 15: 307-307, 2020. |
|---|
|
|
P-126. The current situation investigation and DVO simulation evaluation of the quantity of disposal of injectable anticancer agent in our hospital 松井諒, 岡田沙知, 中村鴻介, 冨岡明絵, 三上友寛, 小西実可子, 山本圭恵, 山口瑞彦, 遠藤正憲 Journal of Japanese Society of Pharmaceutical Oncology 15: 308-308, 2020. |
|---|
|
|
P-127. The clinical usefulness of the examination for NCC yew panel in the clinical sequence and future problem 北見繭子1), 角南久仁子1), 久保崇1), 小山隆文2), 柿島裕樹1), 川村公彦1), 市川仁3), 河野隆志4), 山本昇2), 松下弘道1) Journal of Japanese Society of Pharmaceutical Oncology 15: 309-309, 2020. |
|---|
|
|
P-128. Tendency investigation of the elderly people polypharmacy in patients with cancer during ambulant treatment 高橋健市 Journal of Japanese Society of Pharmaceutical Oncology 15: 310-310, 2020. |
|---|
|
|
P-129. Examination of a drug costs reduction effect by the DVO introduction in azacitidine and the introduction effect in the outpatient department 串亮太, 杉富行, 才郷博久, 花井誉, 高畠啓輔 Journal of Japanese Society of Pharmaceutical Oncology 15: 311-311, 2020. |
|---|
|
|
Member of Japanese clinical tumor Pharmaceutical Society fact-finding 2019 results report 畠山智明, 荒木玲子, 井上裕貴, 大里洋一, 小笠原信敬, 小暮友毅, 笹津備尚, 本田泰斗, 吉村知哲, 湧井宣行, 松井礼子 Journal of Japanese Society of Pharmaceutical Oncology 15: 312-312, 2020. |
|---|
|
|
P-130. Efforts of the checkpoint inhibitor proper use promotion in our hospital of immunity and the evaluation 岡田悠美, 安藤尚美, 皆川卓也, 茂原圭祐, 桝茂典, 櫻井彩乃, 中川隼一, 蔭山博之, 平島徹 Journal of Japanese Society of Pharmaceutical Oncology 15: 313-313, 2020. |
|---|
|
|
P-131. Making of the adverse event expression situation of the Abemaciclib in our hospital and the instruction to patient tool 渡邊小百合, 藤原康浩, 岸本靜佳, 鹿島孝子 Journal of Japanese Society of Pharmaceutical Oncology 15: 314-314, 2020. |
|---|
|
|
P-134. Efforts in the cancer chemotherapy preaudit of our hospital 川合沙季, 高木明子, 津田優理香, 高本裕子, 永沼智至, 長島裕樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 316-316, 2020. |
|---|
|
|
P-135. Activity report of patients with foreign cancer medication counseling duties 引野真由美 Journal of Japanese Society of Pharmaceutical Oncology 15: 317-317, 2020. |
|---|
|
|
P-136. Risk factor search of the serious neutropenia due to CPT-11 鈴木直哉, 菊地義明, 藤林遼, 山田将悟, 朝倉幹己, 藤田果那, 山本翔太, 庄崎沙耶, 田中耕太, 木下愛, 前川英輝, 高橋誠, 青田忠博 Journal of Japanese Society of Pharmaceutical Oncology 15: 318-318, 2020. |
|---|
|
|
P-137. About association of chemotherapy-induced peripheral neuropathy and diabetes 車塚千穂, 奈良悠汰, 川口翔平, 加藤梢, 今井隆人, 小林龍 Journal of Japanese Society of Pharmaceutical Oncology 15: 319-319, 2020. |
|---|
|
|
P-138. About current situation and irAE of the checkpoint inhibitor administration in the small and medium size hospital of immunity 川田亮, 春原龍矢 Journal of Japanese Society of Pharmaceutical Oncology 15: 320-320, 2020. |
|---|
|
|
P-139. Examination of Lenvatinib starting doses in our hospital in the hepatocellular carcinoma 堀内智裕1), 八汐祥恵1), 大窪悠介1), 堀ノ内志織1), 鶴永大貴1), 中村有莉恵1), 赤星真広1), 上原友美1), 池増鮎美1), 佐多照正1), 平峯靖也2) Journal of Japanese Society of Pharmaceutical Oncology 15: 321-321, 2020. |
|---|
|
|
P-140. Need-related investigation that we arrive of the antihistamine for hypersensitivity of the oxaliplatin origin 川田彰彦1), 千葉里菜1), 佐々木崇1), 高橋舞1), 西和哉1), 大堀久詔2), 佐賀利英1,3) Journal of Japanese Society of Pharmaceutical Oncology 15: 322-322, 2020. |
|---|
|
|
P-141. Approach of the closed system anesthesia drug transportation system (CSTD) introduction 沖田直美, 初鹿野達也, 松林麻里子, 城田幹生 Journal of Japanese Society of Pharmaceutical Oncology 15: 323-323, 2020. |
|---|
|
|
P-142. Effect on effect of treatment by the steroid combination at use of nivolumab 榊間絢子, 水谷妙子, 粟野原幸恵, 登内盛治 Journal of Japanese Society of Pharmaceutical Oncology 15: 324-324, 2020. |
|---|
|
|
P-143. Comparison of the pharmaceutical intervention effect in the classification of the oral anticancer medicine 川田史朗, 濱島奈津希, 東垂水裕和, 常本稚奈, 亀村大 Journal of Japanese Society of Pharmaceutical Oncology 15: 325-325, 2020. |
|---|
|
|
P-144. It is examination ... of grasp and the intervention method of ... development situation for immune-mediated adverse event (irAE) measures reinforcement 高木淳也, 寺島聡子, 名和亜利沙, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 15: 326-326, 2020. |
|---|
|
|
P-145. Investigation about the effect on renal function by the hydration change of the chemotherapy, radiotherapy simultaneous therapy in patients with head and neck cancer 熊崎満菜, 岩西雄大, 中野寛之, 高木麻里, 吉田智江, 藤田敬子 Journal of Japanese Society of Pharmaceutical Oncology 15: 327-327, 2020. |
|---|
|
|
P-146. Examination about infusion reaction frequencies by the difference in anticancer agent administration order in the R-CHOP therapy 青柳友彦, 香取哲哉, 河本怜史, 木村敦, 出雲貴文 Journal of Japanese Society of Pharmaceutical Oncology 15: 328-328, 2020. |
|---|
|
|
P-148. Investigation about the injection site reaction with the azacitidine hypodermic injection 藤田強記1), 高武嘉道2), 鶴崎泰史1), 花田聖典1), 中川義浩1) Journal of Japanese Society of Pharmaceutical Oncology 15: 330-330, 2020. |
|---|
|
|
P-149. Telephone follow in the foreign cancer medical therapy, analysis and evaluation examination of tracing report contents 下村直樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 331-331, 2020. |
|---|
|
|
P-150. Evaluation of the pharmacist ambulatory service in the Tokushima Prefectural center Hospital 坂本充司, 小林加奈, 高木友里, 岡田幸大, 國岡恵里佳, 濱口智亘, 鎌田和代 Journal of Japanese Society of Pharmaceutical Oncology 15: 332-332, 2020. |
|---|
|
|
P-151. Elderly people evaluation using the G8 score for the diffuse large B-cell lymphoma and investigation of the incidence of adverse event of the R-CHOP therapy 水野彩花, 福岡智宏, 山本泰大, 宇都宮純平, 戸田康裕 Journal of Japanese Society of Pharmaceutical Oncology 15: 333-333, 2020. |
|---|
|
|
P-152. Comparison about the side effect expression after primary treatment and the second treatment of Osimertinib in the non-small cell lung cancer 小橋来海1), 梅原健吾2), 山佳織1), 若本あずさ2), 初山多恵2), 佐藤秀紀1) Journal of Japanese Society of Pharmaceutical Oncology 15: 334-334, 2020. |
|---|
|
|
P-153. Improvement effect on dermatopathy -III of the minocycline application by EGFR-TKI 佐野和美1), 近藤直樹2) Journal of Japanese Society of Pharmaceutical Oncology 15: 335-335, 2020. |
|---|
|
|
P-154. Side effect expression of CPT-11 in patients with colon cancer and examination about the UGT1A1 genetic polymorphism 田邉徹, 尾上博隆, 中村るみ, 永濱良章, 平川尚宏, 南裕司 Journal of Japanese Society of Pharmaceutical Oncology 15: 336-336, 2020. |
|---|
|
|
P-155. Examination for the clinical response of cefozopran for the febrile neutropenia in patients with lung cancer 東恩納司, 牛尾聡一郎, 江角悟, 北村佳久, 千堂年昭 Journal of Japanese Society of Pharmaceutical Oncology 15: 337-337, 2020. |
|---|
|
|
P-156. Fact-finding about the onset of nail disorder with the trastuzumab administration 山本龍世1), 草野淳一1), 吉田理1), 鈴木信也1), 赤木秀子2), 嶋田昌彦3), 林誠一1) Journal of Japanese Society of Pharmaceutical Oncology 15: 338-338, 2020. |
|---|
|
|
P-157. Effect of the Goshajinkigan combination to give to onset of interstitial pneumonia with the gemcitabine + nab-paclitaxel therapy 高廣理佳子, 山本奈歩, 堀祐貴, 嶋田努, 崔吉道 Journal of Japanese Society of Pharmaceutical Oncology 15: 339-339, 2020. |
|---|
|
|
P-158. The use situation investigation of the antiemetic in the L-OHP regimen and examination of the appropriate antiemetic 濱野麻子, 下村真代, 吉野裕統 Journal of Japanese Society of Pharmaceutical Oncology 15: 340-340, 2020. |
|---|
|
|
P-159. The cardiotoxic current situation with the cancer chemotherapy in our hospital 田代聡美, 川野昭, 福重昇吾, 杉慎介, 藤永理恵子 Journal of Japanese Society of Pharmaceutical Oncology 15: 341-341, 2020. |
|---|
|
|
P-160. Patient survey at changes from Nivolumab weight conversion dose in our hospital to a fixed dose 山本浩史, 藤田英一, 日野裕子, 延藤勇, 豊濱隆 Journal of Japanese Society of Pharmaceutical Oncology 15: 342-342, 2020. |
|---|
|
|
P-161. Safe examination in the administration rapid for 90 minutes of rituximab 若月淳一郎1), 佐久間大樹1), 松本香織1), 花輪和己1), 小林義文1), 飯野昌樹2), 山本誠一1) Journal of Japanese Society of Pharmaceutical Oncology 15: 343-343, 2020. |
|---|
|
|
P-162. Investigation of the risk factor of antithrombotic therapy and the deep vein thrombosis at lenalidomide combination of patients with multiple myeloma in our hospital 小西史子, 濱武清範, 酒井ちひろ, 野間敏也, 美和孝之, 小島一晃 Journal of Japanese Society of Pharmaceutical Oncology 15: 344-344, 2020. |
|---|
|
|
P-163. An approach and evaluation of the pharmacist in the checkpoint inhibitor administration of immunity 上原友美, 八汐祥恵, 大窪悠介, 堀ノ内志織, 堀内智裕, 鶴永大貴, 中村有莉恵, 赤星真広, 池増鮎美, 佐多照正 Journal of Japanese Society of Pharmaceutical Oncology 15: 345-345, 2020. |
|---|
|
|
P-164. Study on angiopathic measures with bendamustine 岡本里美, 河野友昭, 井野川徹, 後藤一美 Journal of Japanese Society of Pharmaceutical Oncology 15: 346-346, 2020. |
|---|
|
|
P-165. Examination of the immune-mediated adverse event expression situation in the patients with a merger, the history of the autoimmune disease 鐵野麻美, 平手大輔, 本郷文教 Journal of Japanese Society of Pharmaceutical Oncology 15: 347-347, 2020. |
|---|
|
|
P-166. Effect of the renal function to give to the toxicity of oxaliplatin 奥澤文敏, 槙原克也, 松村友和 Journal of Japanese Society of Pharmaceutical Oncology 15: 348-348, 2020. |
|---|
|
|
P-167. Effect of the proton pump inhibitor combination to give to onset of hypomagnesemia by the panitumumab 西田未奈, 槙原克也, 松村友和 Journal of Japanese Society of Pharmaceutical Oncology 15: 349-349, 2020. |
|---|
|
|
P-168. The proper use investigation of the antiemetic in the SP therapy and examination of the nausea inducer 難波優希, 岩切悦子, 水津智樹, 辰己晃造, 畝佳子, 政道修二 Journal of Japanese Society of Pharmaceutical Oncology 15: 350-350, 2020. |
|---|
|
|
P-169. Examination about the complexity of the number of the prescription drugs in patients with multiple myeloma and prescription contents 長山佳之, 大橋養賢, 大里洋一, 今村有那, 五味緩子, 大塚健太郎, 武内偲乃, 谷地豊 Journal of Japanese Society of Pharmaceutical Oncology 15: 351-351, 2020. |
|---|
|
|
P-170. Examination about the association between toxicity and effect of treatment with the immune checkpoint inhibitor 岸下敬汰1), 大北仁裕2), 羽床琴音2), 村上あきつ2), 奥山浩之2), 西内崇将2), 二宮昌樹1), 辻晃仁2) Journal of Japanese Society of Pharmaceutical Oncology 15: 352-352, 2020. |
|---|
|
|
P-171. The onset situation of the constipation with the serotonin receptor blocker 柿本智広, 尾辻敬子, 武田恵視, 前田加奈子, 岩元富有子, 川床優子, 枚田明 Journal of Japanese Society of Pharmaceutical Oncology 15: 353-353, 2020. |
|---|
|
|
P-172. Fact-finding about the use situation of the antipsychotics in patients with cancer which developed drug-related akathisia and other patients background 藤本泰輔, 五十嵐隆志, 熊澤名穂子, 末永亘, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 15: 354-354, 2020. |
|---|
|
|
P-173. The expression situation of retching, vomiting by TAS-102 in our hospital and the correspondence 尾上博隆, 田邉徹, 中村るみ, 諏訪田純, 永濱良章, 平川尚宏, 南裕司 Journal of Japanese Society of Pharmaceutical Oncology 15: 355-355, 2020. |
|---|
|
|
P-174. About the onset of treatment regimen of the chemoradiotherapy of Durvalumab treated patients in our hospital and immune-mediated adverse event situation 藤井大和 Journal of Japanese Society of Pharmaceutical Oncology 15: 356-356, 2020. |
|---|
|
|
P-175. Investigation about the onset of oxaliplatin hypersensitivity symptom situation in our hospital 山崎富士子1), 岡本広美2), 門川千夏1), 礒本一宏1), 西嶋祐也1), 村上遥子1), 百濟優花1), 樫野勝幸1) Journal of Japanese Society of Pharmaceutical Oncology 15: 357-357, 2020. |
|---|
|
|
P-176. Safe examination of the pemetrexed in elderly people patients 井上貴久1), 櫻田巧1), 柴田高洋1), 山川裕介1), 桐野靖1), 合田光寛1,2), 座間味義人1,2), 中村敏己1), 寺岡和彦1), 石澤啓介1,2) Journal of Japanese Society of Pharmaceutical Oncology 15: 358-358, 2020. |
|---|
|
|
P-177. Examination of TAS102 administration continuance and the side effect prediction using Geriatric Nutritional Risk Index 宮部貴識, 宮城和代, 明石直子, 櫛田宏幸, 足立紗知, 田中美早, 長谷部茂, 佐光留美, 山内一恭 Journal of Japanese Society of Pharmaceutical Oncology 15: 359-359, 2020. |
|---|
|
|
P-178. Usefulness evaluation of "the pharmacist outpatient department" in foreign cancer chemotherapy patients 二階堂恵子, 景秀典, 河野友昭, 高山慎司, 後藤一美 Journal of Japanese Society of Pharmaceutical Oncology 15: 360-360, 2020. |
|---|
|
|
P-179. Investigation of the factor to give adjuvant chemotherapy introduction after the pancreatic cancer technique 菊地義明, 鈴木直哉, 朝倉幹己, 藤田果那, 庄崎沙耶, 田中耕太, 木下愛, 山本翔太, 山田将悟, 前川英輝, 藤林遼, 高橋誠, 青田忠博 Journal of Japanese Society of Pharmaceutical Oncology 15: 361-361, 2020. |
|---|
|
|
P-180. Peripheral neuropathy investigation with oxaliplatin 中村博雄 Journal of Japanese Society of Pharmaceutical Oncology 15: 362-362, 2020. |
|---|
|
|
P-181. Interview it about safety of the fulvestrant in our hospital and examination - pharmacist of the side effect; and - 稲益里映, 田中喜久 Journal of Japanese Society of Pharmaceutical Oncology 15: 363-363, 2020. |
|---|
|
|
P-182. Use experience of olanzapine in the antiemesis purpose 岡田昌之, 馬場亮一, 中司梨紗, 成末まさみ Journal of Japanese Society of Pharmaceutical Oncology 15: 364-364, 2020. |
|---|
|
|
P-183. 1 case that readministration was enabled by pre-treatment reinforcement law to the patients whom drug allergy developed in for cisplatin 竹内勉, 森利恵, 片岡優子, 矢倉利香, 立山裕美子, 泰松明子, 堀切雅哉 Journal of Japanese Society of Pharmaceutical Oncology 15: 365-365, 2020. |
|---|
|
|
P-185. The case that reached proper use and the improvement of the patients adherence of the cancer chemotherapy supportive care medicine foreign the communication of a health insurance pharmacy pharmacist and the patients 田中寿和, 山崎友里絵, 西澤健太, 堀龍太郎, 長沼敬子, 横井飛太, 染谷光洋, 谷口亮央, 中島史雄 Journal of Japanese Society of Pharmaceutical Oncology 15: 367-367, 2020. |
|---|
|
|
P-186. 1 case that Kamikihito was effective for thrombocytopenia with the chemotherapy 奥村智子1), 岩崎要人1), 松田直之1), 井上浩志2) Journal of Japanese Society of Pharmaceutical Oncology 15: 368-368, 2020. |
|---|
|
|
P-187. Examination of the effectiveness of the naldemedine tosyl acid hydrochloric acid in the cancer classification 富田哲夫, 黒飛謙次, 今井圭介 Journal of Japanese Society of Pharmaceutical Oncology 15: 369-369, 2020. |
|---|
|
|
P-188. One patient who Monthly gives Nivolumab to patients with lung cancer metastases to brain, and responds for a long term 福重昇吾1), 川野昭1), 田代聡美1), 杉慎介1), 山下翔2), 河口知充2), 藤永理恵子1) Journal of Japanese Society of Pharmaceutical Oncology 15: 370-370, 2020. |
|---|
|
|
P-189. The expression situation of the adverse event in the Palbociclib and relation in the pharmacist outpatient department 矢留徹, 弓削理恵子, 相澤学 Journal of Japanese Society of Pharmaceutical Oncology 15: 371-371, 2020. |
|---|
|
|
P-190. It is the case that, however, developed febrile neutropenia using the PEG-GCSF preparation after the small-cell lung cancer regimen administration 畠山朋樹, 石森雅人, 佐藤麻理, 松本光司 Journal of Japanese Society of Pharmaceutical Oncology 15: 372-372, 2020. |
|---|
|
|
P-191. An example of pancytopenia (irAE) which occurred during platinum combination therapy +pembrolizumab treatment in the non-small cell lung cancer 松尾拓馬1), 石原溶子1), 渡邊景明2) Journal of Japanese Society of Pharmaceutical Oncology 15: 373-373, 2020. |
|---|
|
|
P-192. The case that caused crystal separation in the administration for paclitaxel 24 hours 平岩あずさ, 佐々木英雄, 大岩由香里, 古田美里, 榊原崇芳, 近藤有, 間瀬悟, 三宅芳男 Journal of Japanese Society of Pharmaceutical Oncology 15: 374-374, 2020. |
|---|
|
|
P-193. Examination of the effect of the Rabeprazole giving it to peripheral neuropathy with oxaliplatin 古賀香織, 橋詰淳哉, 神田紘介, 兒玉幸修, 中村忠博, 佐々木均, 室高広 Journal of Japanese Society of Pharmaceutical Oncology 15: 375-375, 2020. |
|---|
|
|
P-194. One case that PT-INR of the warfarin remedy patients increased by pazopanib administration 高崎新也1), 川崎芳英2), 菊地正史1), 伊藤明宏2), 眞野成康1) Journal of Japanese Society of Pharmaceutical Oncology 15: 376-376, 2020. |
|---|
|
|
P-195. 2 cases that prothrombin time extended to by combination of warfarin, 5-fluorouracil and the tazobactam piperacillin remarkably 堀川美帆, 小山美菜, 赤井文香, 前川麻央, 佐藤祐司, 高橋阿希子, 菊地正史, 眞野成康 Journal of Japanese Society of Pharmaceutical Oncology 15: 377-377, 2020. |
|---|
|
|
P-196. The case that developed Stevens-Johnson syndrome (SJS) after the checkpoint inhibitor administration of immunity 黒崎隆1), 杉山奈津子3), 吉成宏彰1), 橋本竜1,3), 神坐美弥子1), 前澤佳代子3), 内田克紀2), 佐藤淳也1), 百瀬泰行3) Journal of Japanese Society of Pharmaceutical Oncology 15: 378-378, 2020. |
|---|
|
|
P-197. Relation of the pharmacist for the purpose of the adherence maintenance for patients with old stomach cancer 宍倉啓介, 岡野芳彦, 石井紀子, 寺山義泰 Journal of Japanese Society of Pharmaceutical Oncology 15: 379-379, 2020. |
|---|
|
|
P-198. Use experience of the head ice cradle as the hair loss prophylaxis at paclitaxel + Carboplatin therapy enforcement 吉成宏顕1), 橋本竜1,3), 梅田鈴香1), 入野真紀1), 黒崎隆1), 石黒洋2), 杉山奈津子1,3), 佐藤淳也1,3), 百瀬泰行1,3) Journal of Japanese Society of Pharmaceutical Oncology 15: 380-380, 2020. |
|---|
|
|
P-199. An example of Dabrafenib mesilate, the Trametinib dimethyl sulfoxide addition administration in the non-small cell lung cancer of the unresectable progress, recurrence 小野泰明1), 細田敦規1), 松本信彦1), 佐々木誠悟2), 福田利明1) Journal of Japanese Society of Pharmaceutical Oncology 15: 381-381, 2020. |
|---|
|
|
P-200. 1 case that we supplemented with an antihistamine for fever after the gemcitabine administration in the urology department 柴田晃幸, 陣内優, 有冨航平, 畑瀬圭佐 Journal of Japanese Society of Pharmaceutical Oncology 15: 382-382, 2020. |
|---|
|
|
P-201. An example and making of the immune-mediated adverse event-response manual that developed autoimmune encephalitis during nivolumab administration 大井淳史1), 高山良1), 吉本浩子1), 岡田和美2), 岡本志朗3), 祢津智久4), 日浦和徳1) Journal of Japanese Society of Pharmaceutical Oncology 15: 383-383, 2020. |
|---|
|
|
P-202. One case that we were able to control ascitic for progress colon cancer of the ascites by VEGF inhibitor administration 本田隼人, 中田和宏, 羽田竜也, 吉橋諒, 岡部風葉, 木村美由喜 Journal of Japanese Society of Pharmaceutical Oncology 15: 384-384, 2020. |
|---|
|
|
P-203. One patient who examined pharmacokinetics of the Carboplatin in patients with chronic renal failure 山下紗矢佳1), 田井達也1), 元木貴大1), 山口佳津騎1), 田中裕章1), 大西啓右2), 祖父江理2), 加地雅人1), 小坂信二1), 芳地一1) Journal of Japanese Society of Pharmaceutical Oncology 15: 385-385, 2020. |
|---|
|
|
P-204. One case that became available for ambulant treatment of Blinatumomab using a portable spirit smuggling liquid pump 佐藤菜月1), 井上裕貴1), 堀沢知世1), 佐藤舞1), 中井正彦1), 関水匡大2), 服部浩佳2), 前田尚子2), 堀部敬三2) Journal of Japanese Society of Pharmaceutical Oncology 15: 386-386, 2020. |
|---|
|
|
P-205. The onset of effect in the Pembrolizumab administration case on high-frequency microsatellite instability (MSI-High) solid cancer case and adverse event situation 上森美和子1), 坂井大介2), 佐藤太郎2) Journal of Japanese Society of Pharmaceutical Oncology 15: 387-387, 2020. |
|---|
|
|
P-206. It is one patient of HBc antibody-positive patients using mesalazine for colitis by the nivolumab 森田一1), 三井満里奈1), 平田藍1), 藤本瑛介2), 蜂須賀智2), 野口陽平3), 小澤俊一郎3), 高橋秀明3), 松崎貴志1), 松本伸行3), 田中恒明1) Journal of Japanese Society of Pharmaceutical Oncology 15: 388-388, 2020. |
|---|
|
|
P-207. An example of the malignant melanoma which developed tumor lysis syndrome (TLS) after giving ipilimumab + nivolumab therapy 早川英子1), 近藤勝弘1), 竹本将士1), 小田隆夫2), 森田明理2), 木村和哲1,3,4) Journal of Japanese Society of Pharmaceutical Oncology 15: 389-389, 2020. |
|---|
|
|
P-208. One case that the possibility of drug interactions of cyclosporine and the warfarin was suggested 鈴木大介1), 石原永梨1), 村井宏道1), 近藤光男1), 岩崎年宏2) Journal of Japanese Society of Pharmaceutical Oncology 15: 390-390, 2020. |
|---|
|
|
P-209. One patient whom immune-mediated pulmonary disorder, liver damage developed in after the Nivolumab+Ipilimumab therapy 2 course enforcement 杉慎介, 川野昭, 福重昇吾, 田代聡美, 藤永理恵子 Journal of Japanese Society of Pharmaceutical Oncology 15: 391-391, 2020. |
|---|
|
|
P-210. Case report of patients with progressive renal cell carcinoma which developed myocarditis by nivolumab ipilimumab combination therapy in our hospital 田井達也1), 香西真衣1), 山下紗矢佳1), 元木貴大1), 山口佳津騎1), 田中裕章1), 常森寛行2), 加地雅人1), 小坂信二1), 杉元幹史2), 芳地一1) Journal of Japanese Society of Pharmaceutical Oncology 15: 392-392, 2020. |
|---|
|
|
P-211. 1 example of the lung cancer that developed a delayed immune-mediated adverse event 竹田あかね1), 井上裕貴1), 天野詩織1), 水谷実花1), 中井正彦1), 山田有里紗2), 坂英雄2), 北川智余恵2) Journal of Japanese Society of Pharmaceutical Oncology 15: 393-393, 2020. |
|---|
|
|
P-212. About 2 cases that developed impaired glucose tolerance after the eribulin administration 松本香織1), 佐久間大樹1), 若月淳一郎1), 花輪和己1), 井上正晴2), 井上正行3), 中込博3), 小林義文1), 山本誠一1) Journal of Japanese Society of Pharmaceutical Oncology 15: 394-394, 2020. |
|---|
|
|
P-213. One case that produced Pasteurella multocida bacteremia during Everolimus administration of patients with recurrent breast cancer 岡本直樹, 岩村高弘, 岩永崇志, 池田敦, 森光保武, 川合恵, 藤井秀一 Journal of Japanese Society of Pharmaceutical Oncology 15: 395-395, 2020. |
|---|
|
|
P-214. Basic examination of gemcitabine liquid preparations-induced vascular pain measures for the proper use of the generic drug 河添仁, 吉浦誠海, 横山雄太, 地引綾, 鈴木小夜, 中村智徳 Journal of Japanese Society of Pharmaceutical Oncology 15: 396-396, 2020. |
|---|
|
|
P-215. Relation as the health insurance pharmacy pharmacist to patients with end-stage cancer of the retardation of mental development 大野(川井)朋子1), 中村仁美1), 原田真一1), 佐藤清美2), 大島みちよ3), 大田和枝2), 田中勝1) Journal of Japanese Society of Pharmaceutical Oncology 15: 397-397, 2020. |
|---|
|
|
P-216. One case that pain control support, the cooperation with the ethical pharmacy pharmacist allowed home care smoothly 岩永崇志1), 岩村高弘1), 荻野裕介1), 島林逸人2), 藤井秀一1) Journal of Japanese Society of Pharmaceutical Oncology 15: 398-398, 2020. |
|---|
|
|
P-217. Measures in the expression situation and our hospital of hypersensitivity in the foreign chemotherapy center 木下智広, 横田智也, 岩田和弥 Journal of Japanese Society of Pharmaceutical Oncology 15: 399-399, 2020. |
|---|
|
|
P-218. It is examination about the effectiveness of the pharmaceutical intervention in the adjuvant chemotherapy after the colon cancer technique in oral anticancer agent alone 石井直人, 遠藤篤, 小村裕子 Journal of Japanese Society of Pharmaceutical Oncology 15: 400-400, 2020. |
|---|
|
|
P-219. Maintenance of the electronic chart regimen system that fitted the chemotherapy for children 大野梨絵1), 浦田修平1), 千阪智美1), 山田愛2), 木下真理子2), 平原康寿1), 池田龍二1) Journal of Japanese Society of Pharmaceutical Oncology 15: 401-401, 2020. |
|---|
|
|
P-220. The actual situation of the regimen management and future problem 齊藤俊一郎, 橋本義宏 Journal of Japanese Society of Pharmaceutical Oncology 15: 402-402, 2020. |
|---|
|
|
P-221. Construction and evaluation of the chemotherapy inspection system using "the chemo file" for new face pharmacists 鶴見莉花, 笠原幸子, 竹澤有紗, 田中健二, 松原重征, 吾妻貴司 Journal of Japanese Society of Pharmaceutical Oncology 15: 403-403, 2020. |
|---|
|
|
P-222. One case that we prepared that is special to perform desensitization of the crizotinib for ROS-1-positive lung cancer 橋本章吾1), 小井土啓一1), 柴田祐司2), 高橋省三1) Journal of Japanese Society of Pharmaceutical Oncology 15: 404-404, 2020. |
|---|
|
|
P-223. Questionary survey about the appropriate use of the in-line filter at the anticancer agent administration 諸角一成1), 佐藤由美子1), 權田結乃1), 吉田典子2), 中前勝視3), 中村康夫1) Journal of Japanese Society of Pharmaceutical Oncology 15: 405-405, 2020. |
|---|
|
|
P-224. Relation ... to a low Mg blood symptom in medical treatment management (PBPM) ... antiEGFR antibody medicine based on the protocol in the foreign chemotherapy center 内藤舞, 本多伸二, 佐分利美帆子, 三松史野, 目黒裕史, 實光由香, 大野恵一, 寸田靖, 村岡淳二 Journal of Japanese Society of Pharmaceutical Oncology 15: 406-406, 2020. |
|---|
|
|
P-225. Construction and fact-finding of the operational system of the agent (BCNU wafer) for 5-aminolevulinic acid (5-ALA) and the carmustine intracerebral custody in the malignant brain tumor enucleation 木村敦, 青柳友彦, 河本怜史, 香取哲哉, 出雲貴文 Journal of Japanese Society of Pharmaceutical Oncology 15: 407-407, 2020. |
|---|
|
|
P-226. Consideration of the exposure findings after the closed system anesthesia drug transportation system introduction 中島敦美1,5), 坪谷綾子1,5), 伊藤由香1,5), 木幡和美2,5), 染谷秀樹3), 津田享志4,5), 坂下裕子1) Journal of Japanese Society of Pharmaceutical Oncology 15: 408-408, 2020. |
|---|
|
|
P-227. Efforts about hepatitis B reactivation measures in our hospital 橋本典也1,4), 川久保昂1), 林靖久1), 古賀聖子1), 松崎寿久2,4), 角田順久3,4) Journal of Japanese Society of Pharmaceutical Oncology 15: 409-409, 2020. |
|---|
|
|
P-228. About efforts for the HBV reactivation prevention in the cancer chemotherapy 黒部健太郎1), 中下俊哉2), 嬉野紀夫3), 松永尚1) Journal of Japanese Society of Pharmaceutical Oncology 15: 410-410, 2020. |
|---|
|
|
P-229. About the number and the system of the anticancer agent preparation of the holiday in the Aomori Prefectural center hospital pharmacy 安田真貴子, 千葉典子, 増田朱美, 木村雅子, 雪田大樹, 成田芽生, 柴田美代子, 山本章二 Journal of Japanese Society of Pharmaceutical Oncology 15: 411-411, 2020. |
|---|
|
|
P-230. The current situation investigation of the immune-mediated adverse event with the immune checkpoint inhibitor in our hospital 樋口浩輔, 斉藤佑輔, 木村謙吾, 加藤浩 Journal of Japanese Society of Pharmaceutical Oncology 15: 412-412, 2020. |
|---|
|
|
P-231. The current situation and measures of the anticancer medicine exposure in the angiography room 松波奈緒美, 平手大輔, 福村真梨絵, 本郷文教 Journal of Japanese Society of Pharmaceutical Oncology 15: 413-413, 2020. |
|---|
|
|
P-232. Investigation according to the foreign hospitalization of incident/accident evasion example by the chemotherapy room charge pharmacist using the effect degree classification 三井満里奈, 森田一, 平田藍, 松崎貴志, 田中恒明 Journal of Japanese Society of Pharmaceutical Oncology 15: 414-414, 2020. |
|---|
|
|
P-234. An investigation of the pharmacist intervention situation for patients receiving outpatient department anticancer agent and examination of the intervention method 寺島聡子, 高木淳也, 名和亜里沙, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 15: 416-416, 2020. |
|---|
|
|
P-235. Examination about the dysfunction thyroid of the molecular target medicine using JADER 松井頌明, 石原慎之, 玉木宏樹, 矢野貴久, 直良浩司 Journal of Japanese Society of Pharmaceutical Oncology 15: 417-417, 2020. |
|---|
|
|
P-236. Making of the side effect table for the purpose of the Grade evaluation unification in the cancer chemotherapy 宍戸桃子, 山本明日香, 辻本高志, 井上靖隆, 加納宏樹, 上田晃, 川本由加里, 後藤仁和 Journal of Japanese Society of Pharmaceutical Oncology 15: 418-418, 2020. |
|---|
|
|
P-237. Association (the second report) of the effect of the diet to give to pharmacokinetics and the physicochemical property of the oral antitumor agents 板垣文雄, 秋山紗弓, 金子昌樹, 前島多絵, 飯島亮介, 渡邊真知子 Journal of Japanese Society of Pharmaceutical Oncology 15: 419-419, 2020. |
|---|
|
|
P-238. Efforts aiming at quality improvement of the cancer medical therapy in the whole Sakai-shi 柳下祐貴子1,11), 田川優介2,11), 小川直希1,11), 鶴島克将1,11), 藤原季美子3,11), 北村瑞穂4,11), 宮川道英5,11), 高山宏6,11), 谷森佳弘7,11), 三盃範晃8,11), 桐子雄志11), 東田美奈9,11), 金田仁孝10,11), 星育子2,11), 安井友佳子1,11), 藤井千賀1,11) Journal of Japanese Society of Pharmaceutical Oncology 15: 420-420, 2020. |
|---|
|
|
P-239. Pharmaceutical intervention and efforts of the pharmacist in the foreign cancer chemotherapy 桂川みき1), 湯澤美和2), 中村裕一1), 須藤大雄1), 坂本和央1), 鈴木千波1), 小原秀治1), 小原郁司1) Journal of Japanese Society of Pharmaceutical Oncology 15: 421-421, 2020. |
|---|
|
|
P-240. About the enforcement of the foreign cancer medical therapy training program for health insurance pharmacy pharmacists 小川直希1), 鶴島克将1), 藤井千賀1), 柳下祐貴子1), 宮川道英3), 安井友佳子1), 石坂敏彦2) Journal of Japanese Society of Pharmaceutical Oncology 15: 422-422, 2020. |
|---|
|
|
P-241. Usefulness of the oral exclusive telephone line (hot line) to an anticancer medicine adverse event evaluation and emergency hospital outpatient department chemotherapy room at the health insurance pharmacy 福島弘之1), 村田勇人2), 縄田修一3,4), 松田枝里5), 丹原由希5), 市倉大輔3,4), 峯村純子3,4), 宮原克明6) Journal of Japanese Society of Pharmaceutical Oncology 15: 423-423, 2020. |
|---|
|
|
P-242. An improvement activity and the results report after the pharmacist outpatient department start for patients with cancer for 3 years 福長豊己1), 西倉教子1), 森川記道1), 高橋恭平1), 大山展弘1), 原田靖子1), 西原昌幸2) Journal of Japanese Society of Pharmaceutical Oncology 15: 424-424, 2020. |
|---|
|
|
P-243. The current situation investigation for the appearance care and future problem 佐藤麻理, 石森雅人, 畠山朋樹, 松本光司, 福田稔 Journal of Japanese Society of Pharmaceutical Oncology 15: 425-425, 2020. |
|---|
|
|
P-244. Utilization ... of approach ... reverse tracing report of the new medicine medicine cooperation from a hospital to the drugstore 新津京介, 中澤紘, 鈴木栄, 長谷部忠史 Journal of Japanese Society of Pharmaceutical Oncology 15: 426-426, 2020. |
|---|
|
|
P-245. About the medicine medicine cooperation using the PRO-CTCAE sheet in patients who received surgical foreign cancer chemotherapy 清水敦也1,2), 長谷川功1), 佐藤秀紀2), 山佳織2), 奥村紀美恵3), 鶴間哲弘4) Journal of Japanese Society of Pharmaceutical Oncology 15: 427-427, 2020. |
|---|
|
|
P-246. Keep the relations with a view of the face connected by correspondence ... hospital training to a Lenvatinib adverse event alive; and ... 新谷裕子1), 塚本弘美1), 熊谷史由2), 袰岩靖子2), 高松謙2), 羽川典江2), 花岡嵩1), 麻生敦子3), 菅野和彦2) Journal of Japanese Society of Pharmaceutical Oncology 15: 428-428, 2020. |
|---|
|
|
P-247. Examination of the usefulness of the reporting by the health insurance pharmacy using the tracing report 木ノ下理惠1), 岡本和加子1), 高木聖子1), 山田里美1), 渡邊真紀1), 福島かおり1), 及川萌子1), 小杉三弥子2), 近藤潤一2), 角圭亮3) Journal of Japanese Society of Pharmaceutical Oncology 15: 429-429, 2020. |
|---|
|
|
P-248. Efforts of the tracing report in the drugstore in the site of the cancer practice cooperation base Hospital 桝本千尋1), 弥永実代子1), 日向祐子1), 久米七恵2) Journal of Japanese Society of Pharmaceutical Oncology 15: 430-430, 2020. |
|---|
|
|
P-249. Questionary survey for the insurance pharmacist who completed the hospital in cancer domain business studies 渡邉泰崇, 伊藤昌裕, 弓削吏司 Journal of Japanese Society of Pharmaceutical Oncology 15: 431-431, 2020. |
|---|
|
|
P-250. Efforts for the indium (111In), yttrium (90Y) ibritumomab tiuxetan-labeled preparation 殿村直也1), 奥村俊一1), 後藤総太郎1), 小林美佳1), 高木優奈2), 藤井菊夫2), 田村郁夫2), 遠藤栄輝2), 待鳥裕美子2), 金政佑典3), 下山達3), 石原溶子1) Journal of Japanese Society of Pharmaceutical Oncology 15: 432-432, 2020. |
|---|
|
|
P-251. Intervention to the tumor lysis syndrome onset prevention by the medical treatment management 酒井由希子, 蘆田普海, 関佳奈子, 大野豊 Journal of Japanese Society of Pharmaceutical Oncology 15: 433-433, 2020. |
|---|
|
|
P-252. Report about the correspondence example of the drugstore pharmacist at safe breaking news (blue letter) announcement 黒田和宏, 桑原勝太 Journal of Japanese Society of Pharmaceutical Oncology 15: 434-434, 2020. |
|---|
|
|
P-253. Approach of the continuous care of the outpatient by the telephone follow-up 三星勇輝 Journal of Japanese Society of Pharmaceutical Oncology 15: 435-435, 2020. |
|---|
|
|
P-254. About the need of the transfer acquisition by purchase between narcotics retail dealers and the operational results 加藤聡1), 水井亮1), 村橋憲2), 溝越智広3), 加藤隆幸4) Journal of Japanese Society of Pharmaceutical Oncology 15: 436-436, 2020. |
|---|
|
|
P-255. Usefulness evaluation ... of the patients interview before intervention - medical examination to the foreign cancer chemotherapy room by the outpatient department charge pharmacist 中野悠馬, 長坂美咲, 貞方わかな, 小池永里子, 松本梨華, 柳田義一 Journal of Japanese Society of Pharmaceutical Oncology 15: 437-437, 2020. |
|---|
|
|
P-256. The questionary survey in the active voice type cancer chemotherapy workshop and the future prospects 谷川大夢, 曽根敦子, 矢野忠, 市川訓 Journal of Japanese Society of Pharmaceutical Oncology 15: 438-438, 2020. |
|---|
|
|
P-257. EQ-5D 5 L investigation for patients with cancer in the Qol drugstore 高橋あゆみ1,2), 長沼未加1), 山尾彰3), 三原潔2), 山中竹春4) Journal of Japanese Society of Pharmaceutical Oncology 15: 439-439, 2020. |
|---|
|
|
P-258. The current situation investigation of the telephone follow-up for the use of drug patients for the medical care 川崎祐介, 渡辺富美子, 新谷菜々子, 関根聖子, 鈴尾美沙, 遠藤珠美, 小溝雪江, 赤坂千尋, 金子実樹, 高野幸泉, 松本涼, 栗原千晶, 下村直樹 Journal of Japanese Society of Pharmaceutical Oncology 15: 440-440, 2020. |
|---|
|
|
P-260. Establishment - cancer chemotherapy side effect control foreign efforts ... of the chemo support outpatient department 松岡佳吾1), 坂下晃哉1), 山本伸洋2), 亀谷朋子2), 久米央子1) Journal of Japanese Society of Pharmaceutical Oncology 15: 442-442, 2020. |
|---|
|
|
P-261. Report of the 2019 Keio University pharmacy school cancer professional workshop 横山雄太1), 川上和宜2), 青森達1), 河添仁1), 服部豊1), 中村智徳1) Journal of Japanese Society of Pharmaceutical Oncology 15: 443-443, 2020. |
|---|
|
|
P-262. Activity report of the cancer medical therapy support team in the Kitasato University Hospital 佐々木寿子1,3), 八柳千春2,3), 高橋かおる2,3), 田村和敬1,3), 稲野寛1,3), 厚田幸一郎1,4), 佐々木治一郎3) Journal of Japanese Society of Pharmaceutical Oncology 15: 444-444, 2020. |
|---|
|
|
P-264. Evaluation of the administration situation and the effectiveness of the naldemedine for the opioid-induced constipation 石原正志, 船渡三結, 星野良, 小林亮, 鈴木昭夫 Journal of Japanese Society of Pharmaceutical Oncology 15: 446-446, 2020. |
|---|
|
|
P-265. Examination of the drug costs reduction effect by the change to Biosimilar on the DVO operation of the trastuzumab in the Fukuyama Municipal Hospital 岩村高弘, 藤井秀一, 森光保武, 落葉尚子, 尾高登美枝, 神原史織, 岡本直樹, 岩永崇志 Journal of Japanese Society of Pharmaceutical Oncology 15: 447-447, 2020. |
|---|
|
|
P-266. 1 fact-finding - - of the health insurance pharmacy performing meeting a demand of oral anticancer medicine in cancer practice cooperation base Hospital neighborhood institution 櫻井洋臣1), 村田梓2), 鈴木真也3), 川澄賢司3), 青森達1,4), 加藤裕芳2) Journal of Japanese Society of Pharmaceutical Oncology 15: 448-448, 2020. |
|---|
|
|
P-267. 2 fact-finding - - of the drugstore pharmacist performing meeting a demand of oral anticancer medicine at cancer practice cooperation base Hospital neighborhood drugstore 村田梓1), 櫻井洋臣2), 鈴木真也3), 川澄賢司3), 青森達2,4), 加藤裕芳1) Journal of Japanese Society of Pharmaceutical Oncology 15: 449-449, 2020. |
|---|
